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ABSTRACT OF DISSERTATION

ESTIMATING DISEASE SEVERITY, SYMPTOM BURDEN AND HEALTHRELATED BEHAVIORS IN PATIENTS WITH CHRONIC PULMONARY DISEASES

Chronic pulmonary diseases include a wide range of illnesses that differ in etiology,
prevalence, symptomatology and available therapy. A common link among these illnesses
is their impact on patients’ vital function of breathing, high symptom burden and
significantly impaired quality of life.
This dissertation research evaluates disease severity, symptom burden and health
behaviors of patients with three different chronic pulmonary conditions. First, alpha-1
antitrypsin deficiency (AATD) is an inherited condition that typically is associated with an
increased risk of early onset pulmonary emphysema. This study examines differences in
demographic, health, and behavioral characteristics and compares clinical outcomes and
health related behaviors and attitudes between two severe genotypes of AATD - ZZ and
SZ. The findings of the study suggest that patients with SZ genotype and less severe form
of deficiency report higher number of exacerbations, comorbidities, as well as unhealthy
behaviors such as lack of exercise and current smoking. In addition, individuals with the
more severely deficient ZZ genotype are more adherent to disease management and
prevention program recommendations and maintain a healthier lifestyle than individuals
with SZ genotype.
Second chronic lung disease examined in this research was chronic obstructive
pulmonary disease (COPD), the fourth leading cause of death and second leading cause of
disability in the United States. Prevalence and burden of cough and phlegm, two of the
most common symptoms of the COPD, were assessed among participants of the COPD
Foundation’s Patient-Powered Research Network (COPD PPRN). In addition, association
between patient-reported levels of phlegm and cough, clinical outcomes and patients’
quality of life were evaluated. Participants’ quality of life was assessed using Patient
Reported Outcome Measurement Information System instrument PROMIS-29.
Association between changes in symptom severity over time and patient-reported quality
of life were examined. Findings of this study indicated that severity of cough and phlegm
were associated with higher number of exacerbations, greater dyspnea, and worsened

patient-reported quality of life including physical and social functioning. Improvement in
cough and phlegm severity over time was associated with better patient-reported quality of
life.
Third pulmonary illness described in this dissertation is non-cystic fibrosis
bronchiectasis (NCFB), a rare and etiologically diverse condition characterized by dilated
bronchi, poor mucus clearance and susceptibility to bacterial infection. Association
between presence of Pseudomonas aeruginosa (PA), one of the most frequently isolated
pathogens in patients with NCFFB, and disease severity was assessed utilizing enrollment
data from the Bronchiectasis and NTM Research Registry (BRR). NCFB disease severity
was evaluated using modified versions of validated in large international cohorts
instruments, the Bronchiectasis Severity Index (BSI) and FACED. The findings of this
study indicate that PA infection is common in NCFB patients, and presence of PA in
patients’ sputum is associated with having moderate and high severity of bronchiectasis.
In addition, the results of this study suggest that the two severity assessment instruments
classify patients with NCFB differently which may be attributed to a greater number of
severity markers utilized in the calculation of the BSI compared to FACED.
In conclusion, the proposed dissertation aims to enhance understanding of
differences in health outcomes between genotypes of AATD within AlphaNet registry, and
to guide future health-promoting behaviors. It highlights the burden of common symptoms
such as cough and phlegm in patients with COPD within COPD PPRN and their association
with patients’ quality of life. In addition, it introduces modified indices of NCFB severity
and emphasizes high burden of the disease in patients with presence of PA within US BRR.
KEYWORDS: Lung disease, Symptom burden, Disease severity, COPD, Bronchiectasis,
Alpha1-antitrypsin deficiency.

Radmila Choate
(Name of Student)
03/04/2019
Date

ESTIMATING DISEASE SEVERITY, SYMPTOM BURDEN AND HEALTHRELATED BEHAVIORS IN PATIENTS WITH CHRONIC PULMONARY DISEASES
By
Radmila Choate

Erin L. Abner, PhD, MPH
Director of Dissertation
Steven R. Browning, PhD, MSPH
Director of Graduate Studies
03/04/2019
Date

DEDICATION
To my beloved son Ben who has inspired me to pursue my dreams and to complete
this dissertation research

ACKNOWLEDGMENTS
This dissertation research would not have been possible without the guidance and
efforts of my Dissertation Committee. I would like to express my deepest appreciation to
my dissertation advisor and chair, Dr. Erin Abner, for the continuous support, motivation
and immense knowledge. My sincere thanks goes to Dr. Steve Browning, the DGS for the
Epi/Bio PhD and my dissertation committee member, for his endless support and
guidance throughout this research and the entire PhD program journey. My deepest
gratitude goes to Dr. David Mannino, my mentor and committee member, who has
introduced me to the world of chronic pulmonary diseases and provided clinical expertise
and support in the development of this dissertation research. I would also like to thank my
committee member, Dr. Phil Westgate, for being a great source of knowledge and for
sharing his constructive suggestions for this dissertation. Finally, I would like to thank
my outside examiner, Dr. Patricia Freeman, for agreeing to serve on my committee and
for her insightful feedback related to this research. I also would like to acknowledge and
thank AlphaNet and Dr. Robert Sandhaus, the COPD Foundation and Dr. Barbara Yawn,
the BRR and Dr. Timothy Aksamit, as well as Ms. Malanga, Ms. Pasquale, Ms. Prieto,
and many other collaborators for their continued support and for allowing me to utilize
their data for my dissertation research. I would like to extend my gratitude to the
participants of AlphaNet, the COPD PPRN, and the BRR for their participation that made
this research possible.

iii

TABLE OF CONTENTS

ACKNOWLEDGMENTS ................................................................................................. iii
LIST OF TABLES ............................................................................................................. vi
LIST OF FIGURES .......................................................................................................... vii
CHAPTER 1.

INTRODUCTION .................................................................................. 1

CHAPTER 2.

COMPARING PATIENTS WITH ZZ VERSUS SZ ALPHA-1

ANTITRYPSIN DEFICIENCY WITHIN ALPHANET’S DISEASE MANAGEMENT
PROGRAM

................................................................................................................. 7

Abstract ........................................................................................................................... 7
2.1 Introduction ............................................................................................................. 8
2.2 Methods................................................................................................................. 10
2.3 Results ................................................................................................................... 11
2.4 Discussion ............................................................................................................. 14
2.5 Conclusion ............................................................................................................ 18
CHAPTER 3.

THE BURDEN OF COUGH AND PHLEGM IN CHRONIC

OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS WITHIN THE COPD
PATIENT-POWERED RESEARCH NETWORK (PPRN) ............................................. 27
Abstract ......................................................................................................................... 27
3.1 Introduction ........................................................................................................... 28
3.2 Methods................................................................................................................. 29
3.3 Results ................................................................................................................... 34
3.4 Discussion ............................................................................................................. 39
3.5 Conclusion ............................................................................................................ 43
CHAPTER 4.

PSEUDOMONAS AERUGINOSA ASSOCIATED WITH SEVERITY

OF NON-CYSTIC FIBROSIS BRONCHIECTASIS MEASURED BY THE

iv

BRONCHIECTASIS SEVERITY SCORE (BSI) AND THE FACED: THE US
BRONCHIECTASIS AND NTM RESEARCH REGISTRY (BRR) STUDY ................ 57
Abstract ......................................................................................................................... 57
4.1 Introduction ........................................................................................................... 58
4.2 Methods................................................................................................................. 60
4.3 Results ................................................................................................................... 64
4.4 Discussion ............................................................................................................. 68
4.5 Conclusion ............................................................................................................ 74
CHAPTER 5.

CONCLUSION ..................................................................................... 83

5.1 Summary ............................................................................................................... 83
5.2 Strengths and Limitations ..................................................................................... 86
5.3 Future Research .................................................................................................... 88
REFERENCES ............................................................................................................... 91
VITA

............................................................................................................... 99

v

LIST OF TABLES
Table 2.1 Select demographic and clinical characteristics of the overall sample and
stratified by genotype ........................................................................................................ 19
Table 2.2 Exacerbations, hospitalizations, oxygen use and physician visits in the overall
sample and stratified by genotype..................................................................................... 20
Table 2.3 Frequencies of the comorbidities reported by the respondents in the overall
sample and stratified by genotype..................................................................................... 21
Table 2.4 Self-reported health behaviors and fitness characteristics in the overall sample
and by genotype ................................................................................................................ 23
Table 2.5 Results of adjusted analyses comparing patients with SZ versus ZZ genotype
........................................................................................................................................... 25
Table 3.1 Select demographic and clinical characteristics of the study participants ...... 45
Table 3.2 Cross-tabulation of cough and phlegm severity categories............................. 49
Table 3.3 Pearson correlations, means and standard deviations associated with the
PROMIS-29 domains ........................................................................................................ 50
Table 3.4 PROMIS-29 T-scores in the overall sample and stratified by cough and
phlegm severity levels at baseline..................................................................................... 51
Table 3.5 Changes in severity levels of cough and phlegm between baseline and followup....................................................................................................................................... 52
Table 4.1 Select baseline characteristics of the study population within the BRR
stratified by presence of PA .............................................................................................. 75
Table 4.2 m-BSI severity markers distribution in the overall study sample and stratified
by PA presence ................................................................................................................. 76
Table 4.3 m-FACED severity markers distribution in the overall study sample and
stratified by PA presence .................................................................................................. 78
Table 4.4 Severity of bronchiectasis by m-BSI and m-FACED in the overall study
sample and stratified by presence of PA at baseline including and excluding PA from the
severity scores calculation ................................................................................................ 79
Table 4.5 Classification of bronchiectasis severity by m-BSI versus m-FACED .......... 80
Table 4.6 Results of the unadjusted and adjusted multinomial logistic regressions for
outcomes m-BSI and m-FACED including and excluding PA from the severity scores
calculation ......................................................................................................................... 81

vi

LIST OF FIGURES
Figure 2.1 Study sample flow diagram ........................................................................... 26
Figure 3.1 Cough and phlegm CAT scales ..................................................................... 53
Figure 3.2 Study Flow Diagram...................................................................................... 54
Figure 3.3 PROMIS-29 T-scores at baseline by severity of cough and phlegm ............. 55
Figure 3.4 . PROMIS-29 T-scores at follow-up by severity changes in cough and phlegm
between baseline and follow-up........................................................................................ 56
Figure 4.1 Distribution of m-BSI and m-FACED categories in the overall cohort and
stratified by PA presence .................................................................................................. 82

vii

CHAPTER 1.

INTRODUCTION

Chronic pulmonary diseases, which include a wide range of illnesses of various
lung structures, represent a growing public health problem and affect over a billion of
people of all ages throughout the world.1,2 In the United States, chronic lower respiratory
diseases are the fourth leading cause of death.3 Some of these illnesses are preventable
and curable, while others still have no treatment available.4
Despite the heterogeneity in their etiology, prevalence and presentation, all
chronic pulmonary diseases affect individuals’ lungs and hence the vital act of breathing.4
The burden of these conditions on people’s daily lives, as well as the economic burden to
society in view of lost productivity, disability and healthcare costs is immense.
Exacerbations, or acute flare-ups of symptoms, are common in people with chronic
respiratory diseases, and associate with decreases in health-related quality of life
(HRQOL) and increases in disease-associated mortality.5
Many respiratory diseases, such as Chronic Obstructive Pulmonary Disease
(COPD) remain highly prevalent in the United States (US) and worldwide. In 2015, over
15 million adults in the US reported ever receiving a COPD diagnosis.6 In fact, the actual
prevalence might be significantly higher considering that over 12 million adults may have
undiagnosed COPD due to variations in diagnostic criteria.7,8 COPD is a heterogeneous
group of conditions that include chronic bronchitis, emphysema, and asthma
components.9 It is characterized by symptoms related to airflow obstruction, such as
chronic cough and production of sputum, dyspnea on exertion and wheezing.7 Presence
of these symptoms along with the recurrent lower respiratory tract infections, history of
risk factors such as smoking, environmental and genetic factors, and family history of
1

COPD, in an individual over age of 40 may indicate COPD and requires spirometry to
establish a diagnosis.10
In COPD patients, burden of the disease is high. COPD patients suffer from
chronic respiratory symptoms, fatigue, and often experience flare-ups of their symptoms
that require physician or emergency room visits, change in therapy regimen, or even
hospital admissions. Some of the main goals of COPD treatment are relief of symptoms
and prevention of future excerbations.11 Previous research consistently found decreased
HRQOL in patients with COPD, and its association with disease severity.11,12 Recent
studies suggest symptom burden to be an appropriate marker for COPD disease
severity.11 Thus, patient-perceived and reported symptom burden should be emphasized
in COPD patient evaluation. HRQOL in patients with COPD is a composite measure that
accounts for many psychological factors and other self-perceived patient experiences.13
Patient-reported outcome measurement tools, such as Patient Reported Outcome
Measurement Information System (PROMIS-29) have been validated and utilized to
assess and incorporate COPD patients’ subjective experience in their disease severity
assessment.
Some illnesses under the umbrella of chronic pulmonary diseases are less
common or even rare. In the US, a disease is considered rare if its prevalence does not
exceed 200,000 individuals, or if it affects a greater number of people, but drug
development and availability costs for the disease might not be potentially recovered
from sales.14,15 Approximately 7,000 rare conditions affect estimated 30 million people in
the US and lead to significant morbidity and mortality.16 Over 80% of rare diseases are
genetically based and many are chronically debilitating.16 Alpha-1 antitrypsin deficiency
2

(AATD) is an autosomal codominant genetic condition that results in the production of
defective Alpha-1 antitrypsin (AAT) protein.17 There are over 200 genetic variants of
AAT. The two most frequent deficient alleles are PiZ and PiS.17 PiZZ genotype results in
very low (below the protective threshold of 50 mg/dL) and PiSZ in below normal (less
than 90 mg/dL) serum concentrations of AAT.18,19 Some researchers consider AATD not
a rare but a rarely diagnosed illness.20 Lung disease in patients with AATD often presents
with symptoms of COPD, and most commonly emphysema, and, thus is often
misdiagnosed. AATD is considered one of the most common metabolic disorders among
individuals of northern European descent.21 Low serum concentration of AAT and
detection of genetic mutation assist in establishing the cause of patients’ COPD
symptoms. AATD is estimated to affect one in 5,000-7,000 individuals in North America.
Smoking, along with other environmental and occupational exposures, is one of the main
factors influencing development of the lung disease regardless of genotype.21 Early
diagnosis, healthy lifestyle, standard therapy for obstructive lung disease and, if
indicated, periodic augmentation therapy to replace the deficient protein are the main
disease management options in patients with AATD-related lung disease.21
Another rarely diagnosed chronic pulmonary disease, non-cystic fibrosis
bronchiectasis (NCFB), is inherently heterogeneous and is characterized by progressive
and irreversible airway damage.22 Due to a complex pathophysiology involving infective,
immune and inflammatory mechanisms, which chronically destruct bronchi in a so called
“vicious cycle”, bronchiectasis patients require specific and long-term management.22,23
Prevalence of NCFB continues to increase which may be explained by a greater
awareness of the disease among clinicians and radiological advancements that aid in
3

accurate diagnosis.22 Some of the main presentations of bronchiectasis include chronic
cough with sputum production, fatigue, hemoptysis, COPD symptoms in non-smokers,
frequent respiratory infections and isolation of sputum pathogens such as Pseudomonas
aeruginosa (PA) or Non-tuberculous mycobacterium (NTM).24 High resolution CT scan
confirms the diagnosis of bronchiectasis.24
Due to the complexity of various symptoms, recurrent exacerbations and
hospitalizations, doctors’ visits, and frequent sputum microbiology and imaging testing,
the burden of bronchiectasis on patients’ lives and healthcare systems is substantial.23,24
Bronchiectasis severity is a multidimensional concept and use of multiple parameters is
needed to capture the complexity of the disease burden and prognosis. The
Bronchiectasis Severity Index (BSI) and the FACED have been developed and validated
to improve the identification of high-risk NCFB patients and to guide therapy
decisions.25,26
The chapters that follow present studies that estimate disease severity, symptom
burden and health-related behaviors in patients with the described above three chronic
pulmonary conditions. In Chapter Two, “Comparing Patients with ZZ versus SZ Alpha-1
Antitrypsin Deficiency within AlphaNet’s Disease Management Program”, demographic,
clinical characteristics and health-related behaviors of patients with two most prevalent
AATD genotypes, PiZZ and PiSZ, are evaluated. The major findings from this study
identified that patients with ZZ and SZ genotypes in AlphaNet’s disease management
program differ in health outcomes and health-related behaviors.27 Patients with SZ
genotype had more comorbidities and were not as engaged in health-promoting behaviors
compared to patients with ZZ genotype. ZZ patients were found to be more adherent to
4

the recommendations of the disease management program and maintained a healthier
lifestyle than SZs.
The study presented in Chapter Three, “The Burden of Cough and Phlegm in
Chronic Obstructive Pulmonary Disease (COPD) Patients within the COPD PatientPowered Research Network (PPRN)” addresses the association between severity of
cough and phlegm and quality of life in patients with self-reported physician-diagnosed
COPD. The findings of this study identified that cough and phlegm severity levels were
associated with higher number of exacerbations, greater dyspnea, and worsened patientreported quality of life including physical and social functioning and mood. The study
results indicated that improvement in cough and phlegm severity over time were
associated with better patient-reported quality of life. Exploration of new treatments
aimed at improvement of cough and phlegm severity in this patient population were
recommended.
Findings presented in Chapter Four, “Pseudomonas aeruginosa Associated with
Severity of Non-cystic Fibrosis Bronchiectasis Measured by the Modified Bronchiectasis
Severity Score (BSI) and the FACED: the US Bronchiectasis and NTM Research
Registry (BRR) Study”, supports previous research that PA infection is common in
patients with NCFB. The study identified that the severity of bronchiectasis is
significantly greater in patients with PA, which emphasizes the high burden of the
disease. This chapter concludes that further collaborative work in this area are needed
including exploration of new management options aimed at the improvement of patient
outcomes and prognosis in PA infected NCFB patients.

5

Chapter Five of this dissertation provides summaries of major findings, discusses
strengths and limitations, and suggests future research recommendations.

6

CHAPTER 2.
COMPARING PATIENTS WITH ZZ VERSUS SZ ALPHA-1
ANTITRYPSIN DEFICIENCY WITHIN ALPHANET’S DISEASE MANAGEMENT
PROGRAM
Abstract
Background: The aim of this study was to examine differences in demographic, health,
and behavioral characteristics in individuals with ZZ and SZ genotypes of alpha-1
antitrypsin deficiency (AATD) within AlphaNet’s Disease Management and Prevention
Program (ADMAPP).
Methods: Self-reported data from 3,535 patients with AATD, including 3,031 (85.7%)
patients with ZZ, ZNull, and NullNull genotypes (referred to here as ZZ), and 504
(14.3%) with the SZ genotype were analyzed using t-tests, ANOVAs, and Chi-squared
tests.
Results: The average age of the cohort was 56.3±10.6 years. The majority of respondents
were males (51.2%), Caucasians (98.2%), and married (65.2%). SZs reported having
more frequent exacerbations (p<0.001) and hospitalizations (p=0.012) than ZZs. A higher
proportion of SZs than ZZs had been diagnosed with high blood pressure, diabetes,
congestive heart failure, and other comorbid conditions. SZs were more likely than ZZs
to report “poor” health (p=0.005). Over a third (38.4%) of SZs do not exercise compared
to 27.1% of ZZs (p<0.001). A greater proportion of SZs compared to ZZs view
themselves as being overweight (p<0.001) or “out of shape” (p=0.001). A higher
proportion of SZs than ZZs reported any history of smoking and current smoking
(p<0.001).
7

Conclusions: In patients with AATD and lung disease participating in a disease
management program, a higher proportion of SZs than ZZs report exacerbations,
comorbidities, and overall poor health, as well as unhealthy behaviors such as lack of
exercise and current smoking. Future work should consider the extent to which genotypespecific health promotion interventions would be useful.

2.1

Introduction
Alpha-1 antitrypsin deficiency (AATD) is an autosomal co-dominant disorder that

results from mutations of the SERPINA1 gene and typically is associated with the
elevated risk of early onset pulmonary emphysema28 in adults, liver disease in children
and adults and, more rarely, necrotizing panniculitis.29
SERPINA1 is considered a polymorphic gene.30 The PiM-allele represents the
normal genotype. The two most common mutations of the gene associated with AATD
are the PiZ and PiS mutations, where Pi stands for “protease inhibitor”.31 Homozygous
PiZZ is the most commonly identified severely deficient genotype while the PiS-allele
leads to a milder plasma deficiency of AAT.30 Over 200 mutations of the gene have been
discovered, with approximately one third of these mutations leading to clinically
significant deficiency.31 Serum levels of AAT between 85 and 215 mg/dL are considered
normal,32 although normal ranges vary by laboratory. Individuals with a ZZ genotype
rarely have levels above 57 mg/dL, and levels below this value are presumed to provide
inadequate lung protection.31

8

Both Z and S mutations are believed to have originated among populations of
European (Caucasian) descent.33 The Z-gene is associated with the Scandinavian/Baltic
region,34 and the S-gene is considered to derive from the Iberian peninsula.35 AATD can
be found in all major racial subgroups in the world, although often at a very low
frequency.36
Previous studies that compared clinical features of SZ and ZZ patients have found
significantly fewer respiratory symptoms, less severe airflow obstruction, and fewer
radiographic lung abnormalities in SZ patients.37 Similarly, a study using the Spanish
AATD registry (REDAAT) determined that ZZs have greater lung function impairment
than SZs.35 The results of a large study in the UK demonstrated similar disease
progression between SZs and ZZs although SZs had better baseline characteristics.38
These findings were explained by the greater importance of AAT levels rather than
genotype.38 Other studies have demonstrated a correlation of serum AAT levels with the
severity of emphysema.39 Smoking is the major risk factor for development of lung
disease in patients with AATD regardless of genotype.40,41
It is important to know whether genotype is associated with health outcomes and
health behaviors, in order to determine whether individuals with the SZ genotype have
differing needs from ZZs with regard to health education and behavioral interventions
such as smoking cessation. The primary aim of this study was to examine differences in
demographic, health, and behavioral characteristics in individuals with ZZ and SZ
genotypes among individuals who are participating in a disease management program
designed for patients with AATD and lung disease.

9

2.2

Methods
The study population consisted of participants of AlphaNet, a not-for-profit health

management organization that coordinates management and treatment of individuals with
AATD and lung disease in the US.42 Enrollment in ADMAPP is offered when an
individual is prescribed plasma-derived, intravenous AAT for the treatment of lung
disease due to AATD (augmentation therapy). Analyses were conducted on de-identified
data collected by AlphaNet. The study was approved by the University of Kentucky
Institutional Review Board (IRB).
The inclusion criteria were that the participants were members of AlphaNet and
had either a ZZ, ZNull, NullNull (analyzed in combination with ZZ) or SZ genotype of
AATD. The final sample included 3,535 respondents (Figure 1). Of these, 3,031 (85.7%)
were identified as ZZs. The ZZs can be broken down as follows: ZZ (n=2,979, 98.3%),
ZNull (n=38, 1.2%), and NullNull (n=14, 0.5%). The present study analyses compared
baseline characteristics of AATD patients with the ZZ genotype to those with the SZ
genotype. All data were collected using questionnaires administered via a telephone
interview.
Statistical analyses
Descriptive statistics were computed for baseline characteristics for the overall
sample and stratified by genotype (ZZ vs. SZ). The results for continuous variables were
reported as mean ( SD), and for categorical variables by frequencies and proportions.
Values between the groups were compared using t-test/ANOVA, and Chi-squared test
respectively. Post-hoc comparison of adjusted standardized residuals was used to
determine the source of the statistically significant Chi-square for categorical variables.
10

Negative binomial (NB) regression models were fit for frequency of exacerbations and
visits to a primary care physician in the past year adjusting for age, sex, smoking status
and Charlson Comorbidity Index (CCI). A zero-inflated negative binomial (ZINB) model
was fit for frequency of hospitalizations adjusting for the same covariates. The
significance level for all analyses was set at 0.05. False discovery rate control was used to
correct for multiple univariate testing.43 SAS 9.4 and SPSS version 22 were used to
conduct analyses.
2.3

Results
Table 2.1 demonstrates the baseline demographic characteristics of the overall

sample (n=3,535) and stratified by genotype: ZZ (n=3,031, 85.7%) and SZ (n=504,
14.3%). Average age of the study population was 56.3±10.6 years. Patients with the ZZ
genotype were slightly younger than SZs (55.9 years vs. 58.6 years, p<0.001), and a
greater proportion of ZZs were Caucasians (98.4% vs. 96.8%, p=0.012), and reported
being married (66.1% vs. 59.3%, p=0.004). The majority of respondents were male
(51.2%) with no significant differences by genotype. Over ninety percent of all the
respondents (92.7%) were on augmentation therapy with a greater proportion of ZZs than
SZs (93.5% vs. 87.1%, p<0.001). The CCI score (which accounts for number and
complexity of comorbidities) was significantly higher among SZs than ZZs (p<0.0001)44.
A total of 3,274 (97.6%) patients reported ever having lung disease, with no
significant difference between the genotypes. Emphysema/chronic bronchitis/COPD
(96.8%) and asthma (37.7%) were the most frequent types of lung disease reported by the
respondents.
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Among those who reported ever having lung disease, significant differences were
found in exacerbation frequency between ZZ and SZ patients (p<0.001, Table 2.2). Based
on post-hoc analysis using standardized residuals, a significantly greater proportion of
SZs than ZZs reported having monthly (20.2% vs. 13.9%) and quarterly (21.3% vs.
16.2%) exacerbations, while ZZs reported more semi-annual exacerbations (13.9% vs.
9.6%). SZs did not differ from ZZs with regard to percent that used oxygen regularly,
number of hours oxygen was used per day, or coughing up sputum regularly.
The average number of visits to the primary care physician over the past year
among all the respondents was 3.2±1.9, and to the lung specialist was 2.9±1.7. The mean
number of hospitalizations was 0.7±1.3. SZs reported more primary physician visits
(p<0.001), lung specialists visits (p<0.001) and hospitalizations (p=0.012) than ZZs.
Table 2.3 presents the frequencies of the comorbidities within the overall study
sample and stratified by genotype. The most frequent comorbidities were high blood
pressure (40.3%), gastroesophageal reflux (34.8%), sinus disease (16.1%), heart rhythm
problems (12.9%) and any tumor/cancer (11.9%). This study found that a statistically
significantly greater proportion of SZs in the cohort were diagnosed with the six most
prevalent comorbidities.
Table 2.4 presents the results of self-reported health behaviors and fitness
characteristics of ZZs and SZs. The majority of respondents reported having ever smoked
(73.1%), and a significantly greater proportion of SZs than ZZs reported having ever
smoked (p<0.001). In addition, SZs are more likely to continue to smoke (p<0.001), have
been smoking longer (p<0.001), and report smoking more packs per day (p<0.001).
Contrary to the findings for smoking, a higher proportion of ZZs report that they
12

consume alcohol (p=.009), and ZZs consume more drinks per week on average than SZs
(p=.030).
In view of self-perceived health and fitness, a significantly greater proportion of
SZs than ZZs perceive themselves as being overweight (p<0.001), out of shape (p=0.001)
and in “poor health” (p=0.005). More ZZs report that they exercise regularly compared to
SZs, and 38.4% of SZs do not exercise at all compared to 27.1% ZZs (p<0.001).
The majority of patients reported that they follow the guidelines of ADMAPP
(53.5%), and a significantly greater proportion of ZZs report following the program
compared to SZs (p=0.026). Almost a half of the participants (49.2%) reported ever
reading the BFRG with no difference by genotype.
Most patients reported being very comfortable with their knowledge about AATD
(51.1%). However, significant differences were found between the genotypes (p<0.001).
Specifically, a greater proportion of SZs, when compared to ZZs, reported being either
“not comfortable” (9.8% vs. 4.0%) or “somewhat comfortable” (55.0% vs. 42.2%) with
knowledge about their condition.
Table 2.5 presents results of the adjusted NB and ZINB models. The criteria for
assessing goodness of fit of each of the regression models showed adequate fit: deviance
(scaled deviance) value/DF and Pearson Chi-Square (Scaled Pearson) value/DF were
reasonably close to 1 (between 0.95 and 1.18) which indicates adequate fit of the models
to the data. The selected regression models showed superior fit using Vuong test and
AIC, AICC, and BIC criteria, when compared to other types of count models.
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As demonstrated in Table 2.5, genotype was associated with the number of
exacerbations and visits to a primary care physician after adjusting for age, gender,
current smoking status, and CCI score. SZs had 1.21 times the rate of pulmonary
exacerbations (IRR=1.21, 95% CI: 1.05-1.40) and visits to a primary care physician
(IRR=1.21, 95%CI: 1.12-1.30) in the past year compared to ZZs.
2.4

Discussion
Earlier work by Turino et al.37 described clinical features of a relatively small

number of patients with the SZ genotype of AATD and AAT concentrations above or
below 11 µM (~57 mg/dL), including the effects of smoking on development of lung
disease in SZs. More recent studies comparing characteristics of individuals with the ZZ
and SZ genotypes were mainly carried out in Europe35,38,45 as the prevalence of S-allele is
the highest in the general population of Spain and Portugal (17.3 and 13.8 per 1,000,
respectively).46
Although any individual with AATD can enroll in AlphaNet’s disease
management program, the vast majority of individuals entered because of a prescription
for augmentation therapy for lung disease due to AATD. Individuals not receiving
augmentation therapy are moved to a different program within AlphaNet that focuses on
risk reduction: Risk Evaluation to Ensure Continued Health (REACH). Thus, the
population described here is greatly enriched for individuals with lung disease due to
AATD. Since individuals with the SZ genotype are considerably less likely to develop
lung disease than ZZs,37 many of the differences reported in this study may be reflective
of the subpopulation of SZs with risk factor exposure sufficient to have led to clinically
significant lung disease. Risk for development of lung disease is associated with the
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interaction between genetic factors and various environmental exposures such as
smoking.40
Prior studies have noted higher mean smoking consumption of SZs compared to
ZZs.47 This study findings complement these observations by showing that when
compared to ZZs, SZs had a significantly longer smoking history with greater number of
packs smoked per day. Further, the SZs in our sample were more likely to continue
smoking after being diagnosed with lung disease. These results reflect the importance of
emphasizing behavioral interventions and health education including smoking cessation,
especially among SZs, as well as early diagnosis of AATD prior to the development of
heavy smoking habits.47
Exacerbations commonly occur among patients with AATD-related lung disease48
and, in previous research, were demonstrated to be associated with a decline in lung
function.48 In our sample, SZs reported more frequent exacerbations than ZZs, even after
adjusting for age, sex, current smoking status and CCI score. Possible explanations
include greater prior exposure to smoking, and lower adherence to healthy lifestyle
recommendations, including adherence to AlphaNet’s disease management program.
However, lack of pulmonary function data limited our ability to compare lung disease
severity between genotypes.
Previous research has demonstrated an association between AATD and certain
comorbidities, such as ulcerative colitis and hypothyroidism49 among ZZs. Other studies
demonstrated associations between ZZ and MZ genotypes of AATD and reduced blood
pressure, as well as MZ and reduced risk of ischemic cerebrovascular and ischemic heart
disease.50,51 This study results show a significantly higher prevalence of cardiovascular
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comorbidities, including hypertension, cerebrovascular disease, congestive heart failure,
and arrhythmia among SZs compared with ZZs. The reasons for this association with SZ
genotype are not well understood, nor sufficiently investigated previously. It should be
noted that SZs in our cohort are slightly older than ZZs; also, the diagnosis of AATD
may prompt a more thorough assessment for other health problems among SZs.
Additionally, our findings of unhealthy lifestyle of the majority of SZs in this study
population, may have contributed to the greater prevalence of cardiovascular
comorbidities among patients with this genotype.
Previous research has explored the effects of genetic information on health
behaviors of patients and their families.52-56 These studies have found inconsistent results
with regard to the effect of genetic information on smoking cessation and motivation to
improve diet and physical activity. The present study demonstrated that ZZs and SZs
significantly differ in their perception of health and fitness as well as their health
behaviors. A greater proportion of SZs viewed themselves as overweight, out of shape
and in poor health, and they also exercise less and report heavier and longer history of
smoking compared with ZZs in our study. These findings may be explained by the
perception that the SZ genotype presents a lower risk of the disease in view of the higher
AAT levels in plasma. Our findings with regard to alcohol consumption suggest that,
regardless of genotype, additional education about moderation of alcohol consumption
should be considered due to the increased risk of liver disease among individuals with
AATD.
ADMAPP is a vital part of AlphaNet’s commitment to improve patients’ health
outcomes.42,57 The present study shows that a significantly lower proportion of SZs report
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following the guidelines of ADMAPP compared to ZZs. This lower adherence to the
program may be due to the earlier mentioned concept of the low self-perceived
seriousness of their condition. It should also be noted that SZs are less comfortable with
the level of their knowledge about AATD compared to ZZs.
Our results suggest that, among individuals with AATD who have developed lung
disease, people with a less severe genotype who develop lung disease have worse health
outcomes and health behaviors. Thus, the people who are less at risk (from a genetic
standpoint) to develop lung disease may actually do worse once they have developed
lung disease. While prevention efforts may need to be targeted to ZZs (since they are
most at risk to develop disease) it is possible that disease management may be even more
vital to SZs.
Understanding differences and similarities between various genotypes of AATD
is of great importance from the public health perspective. Early knowledge and
awareness of AATD allows for timely testing, smoking prevention and cessation, and
initiation of augmentation therapy when indicated.58
Strengths and limitations
The main strengths of the present study include a large number of patients with
AATD-related lung diseases enrolled in the disease management program, as well as
unique data on multiple health-related behaviors collected by AlphaNet.
Several limitations must be acknowledged. First, a considerably larger fraction of
ZZs develop lung disease compared with SZs. Since only patients with lung disease were
invited to participate in ADMAPP, this may have introduced ascertainment bias into the
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study. Although, both SZs and ZZs were enrolled based on the presence of lung disease.
This study provides no information about the comparative characteristics of SZs and ZZs
without lung disease. Second, causality cannot be inferred due to the cross-sectional
design of this study. Third, objective data were not available to provide more specifics on
clinical phenotyping of lung disease, including CT findings and lung function
measurements. Another limitation of this study is unavailability of the actual date of
AATD diagnosis in most patients, which limits our ability to account for the length of
time since diagnosis. The benefits of earlier age at diagnosis might be reflected in
behavior modifications such as smoking cessation or improved exercise habits, which
might contribute to better outcomes.
2.5

Conclusion
In summary, the results of this study document that ZZ and SZ patients in

AlphaNet’s disease management program differ with regard to health outcomes and
health behaviors. Individuals with the SZ genotype report more comorbidities and are
less likely to engage in health-promoting behaviors such as exercise and smoking
cessation. It appears that individuals with the more severely deficient ZZ genotype are
more adherent to ADMAPP recommendations and maintain a healthier lifestyle than
individuals with the less severely deficient SZ genotype. As such, improvements in
education efforts may be especially beneficial for individuals with the SZ genotype who
have lung disease, even though their underlying AATD is considered to be less severe.
Funding Support: This study was funded by an unrestricted research grant from
AlphaNet.
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Table 2.1 Select demographic and clinical characteristics of the overall sample and
stratified by genotype
Data
Total
ZZ
SZ
Pavailable
value
(N=3,535)
(N=3,031)
(N=504)
Age, mean (SD)

3,535

56.3 (10.6)

55.9 (10.5)

58.6 (11.2)

<.001

Male

3,535

1,808 (51.2)

1,535 (50.6)

273 (54.2)

.143

Race/ Ethnicity

3,475

Non-Hispanic
Whitea

.012
3,412 (98.2)

2,935 (98.4)

477 (96.8)

AfricanAmerican

14 (0.4)

13 (0.4)

1 (0.2)

Hispanica

29 (0.8)

20 (0.7)

9 (1.8)

Othera

20 (0.6)

14 (0.5)

6 (1.2)

Married

3,417

2,227 (65.2)

1,938 (66.1)

289 (59.3)

.004

Employed

3,135

1,118 (35.7)

997 (36.8)

121 (28.5)

.002

Augmentation use

2,842

2,634 (92.7)

2,330 (93.5)

304 (87.1)

<.001

History of any
lung disease

3,354

3,274 (97.6)

2,819 (97.7)

455 (96.8)

.336

Emphysema/
Chronic
Bronchitis/ COPD

3,204

3,100 (96.8)

2,681 (96.9)

419 (95.7)

.165

Asthma

3,031

1,144 (37.7)

993 (37.8)

151 (37.2)

.806

Pneumonia

2,995

520 (17.4)

453 (17.4)

670(17.0)

.822

Bronchiectasis

2,999

292 (9.7)

263 (10.1)

29 (7.29)

.077

Charlson
Comorbidity
Index, mean (SD)

3,352

0.68 (1.31)

0.63 (1.25)

0.97 (1.59)

<.0001

Note: All statistics are reported as frequency (percentage) unless otherwise indicated.
a
denotes statistically significant difference based on post hoc analysis using standardized
residuals
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Table 2.2 Exacerbations, hospitalizations, oxygen use and physician visits in the overall
sample and stratified by genotype
Data
Total
ZZ
SZ
Pavailable
(N=3,535)
(N=3,031)
(N=504)
value
Exacerbation frequency of
lung problems over the
past yeara
Every Month c
Every 3 Months c
Every 4 Months
Every 6 Months c
Once
Never
Number of exacerbations
of lung problems over the
past year, mean (SD)
Regular oxygen usea
Regular Oxygen usea,
average hours per day,
mean (SD)
Regularb coughing up
sputum from lungs over the
past 2 yearsa
Primary physician visits
over the past year, mean
(SD)
Lung specialist visits over
the past year, mean (SD)

2,903

<.001
427 (14.7)
489 (16.8)
285 (9.8)
387 (13.3)
615 (21.2)
700 (24.1)

351 (13.9)
409 (16.2)
252 (10.0)
351 (13.9)
546 (21.6)
618 (24.5)

76 (20.2)
80 (21.3)
33 (8.8)
36 (9.6)
69 (18.4)
82 (21.8)

2,903

3.2 (3.9)

3.1 (3.8)

3.9 (4.3)

<.001

2,943

1,515 (51.5)

1,333 (52.2)

182 (46.9)

.053

1,470

15.5 (7.9)

15.6 (7.9)

15.3 (7.9)

.740

2,863

1,228 (42.9)

1,056 (42.3)

172 (46.9)

.099

3,380

3.2 (1.9)

3.1 (1.9)

3.7 (1.9)

<.001

3,382

2.9 (1.7)

2.9 (1.7)

3.2 (1.7)

<.001

Hospitalizations over the
past year, mean (SD)
3,362
0.7 (1.3)
0.6 (1.2)
0.8 (1.3)
.012
Note: All statistics are reported as frequency (percentage) unless otherwise indicated.
a
denotes frequency among patients with any type of lung disease, b denotes frequency of
at least three months per year over the past two years, c denotes statistically significant
difference based on post hoc analysis using standardized residuals

20

Table 2.3 Frequencies of the comorbidities reported by the respondents in the overall
sample and stratified by genotype
Total
ZZ
SZ
P-value
(N=3,535)
(N=3,031)
(N=504)
N=3,099

N=2,668

N=431

High Blood Pressure

1,248 (40.3)

1,024 (38.4)

224 (52.0)

<.001 a

Gastroesophageal reflux
(GERD, heartburn)

1,077 (34.8)

903 (33.9)

174 (40.4)

.008 a

Sinus disease

499 (16.1)

411 (15.4)

88 (20.4)

.009 a

Heart rhythm problem

399 (12.9)

319 (12.0)

80 (18.6)

.001 a

Any tumor or cancer

369 (11.9)

299 (11.2)

70 (16.2)

.003 a

Diabetes

268 (8.7)

195 (7.3)

73 (17.0)

<.001 a

Skin problems (such as
panniculitis)

258 (8.3)

228 (8.6)

30 (7.0)

.269

Pulmonary hypertension

204 (6.6)

169 (6.3)

35 (8.1)

.165

Peripheral vascular disease

199 (6.4)

169 (6.3)

30 (7.0)

.623

Connective tissue disease

192 (6.2)

160 (6.0)

32 (7.4)

.254

Mild liver disease

183 (5.9)

155 (5.8)

28 (6.5)

.580

Ulcer Disease

172 (5.6)

137 (5.1)

35 (8.1)

.012 a

Inflammatory bowel disease

169 (5.5)

138 (5.2)

31 (7.2)

.087

Severe eye problems

136 (4.4)

111 (4.2)

25 (5.8)

.123

Congestive heart failure

119 (3.8)

89 (3.3)

30 (7.0)

<.001 a

Myocardial infarction

108 (3.5)

80 (3.0)

28 (6.5)

<.001 a

Hepatitis

103 (3.3)

83 (3.1)

20 (4.6)

.100

Data available
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Table 2.3 Continued
Total
(N=3,535)
95 (3.1)

ZZ
(N=3,031)
80 (3.0)

SZ
(N=504)
15 (3.5)

P-value

Cerebrovascular disease

91 (2.9)

66 (2.5)

25 (5.8)

<.001 a

Mild kidney disease

72 (2.3)

63 (2.4)

9 (2.1)

.864

Moderate or severe kidney
disease

59 (1.9)

44 (1.7)

15 (3.5)

.010 a

Granulomatosis with
polyangiitis

38 (1.2)

34 (1.3)

4 (0.9)

.812

Paralysis of arms and/or legs

24 (0.8)

16 (0.6)

8 (1.9)

.012 a

Dementia or Alzheimer’s

16 (0.5)

14 (0.5)

2 (0.5)

.999

Metastatic cancer

13 (0.4)

12 (0.5)

1 (0.2)

.999

Lymphoma

11 (0.4)

11 (0.4)

--

--

Leukemia

7 (0.2)

4 (0.2)

3 (0.7)

.061

AIDS

2 (0.1)

1 (0.1)

1 (0.2)

.259

Moderate or severe liver disease

.590

Note: All statistics are reported as frequency (percentage) unless otherwise indicated. a significant results after false discovery rate control
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Table 2.4 Self-reported health behaviors and fitness characteristics in the overall sample
and by genotype
Data
Total
ZZ
SZ
Pavailable
(N=3,535)
(N=3,031)
(N=504)
value
Ever smoking history

3,105

2,270 (73.1)

1,937 (72.0)

333 (80.6)

<.001

Still smoking

2,257

106 (4.7)

68 (3.5)

38 (11.5)

<.001

Max number of packs/
day
Mean (SD)

2,197
1.4 (0.8)

1.4 (0.8)

1.7 (0.9)

<.001

Years of smoking
Mean (SD)

2,162

19.9 (9.9)

18.4 (8.7)

28.5 (11.9)

<.001

Consume alcohol

3,027

1,372 (45.3)

1,216 (46.4)

156 (38.6)

.009

Number of drinks/week
Mean (SD)

1,328

5.4 (6.3)

5.5 (6.5)

4.3 (4.8)

.030

888 (28.6)
1,071 (34.5)
1,144 (36.9)

729 (27.1)
945 (35.1)
1,015 (37.8)

159 (38.4)
126 (30.4)
129 (31.2)

Do you exercise
No a
Irregularly
Regularly a

3,103

Perception of weight
Underweight
About Right a
Overweight a
Perception of fitness
Out of Shape a
Getting Fit
Pretty Fit a
Very Fit
Perception of health
Poor a
Fair
Good
Excellent a
Follow ADMAPP

3,077

<.001

<.001
349 (11.3)
1,249 (40.6)
1,479 (48.1)

299 (11.2)
1,123 (42.1)
1,244 (46.7)

50 (12.2)
126 (30.7)
235 (57.2)

3,054

.001
1,396 (45.7)
606 (19.8)
957 (31.3)
95 (3.1)

1,179 (44.5)
525 (19.8)
860 (32.5)
86 (3.3)

217 (53.7)
81 (20.1)
97 (24.0)
9 (2.2)

3,069

2,412

.005
529 (17.2)
1,272 (41.5)
1,136 (37.0)
132 (4.3)
1,291 (53.5)
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436 (16.4)
1,112 (41.8)
988 (37.2)
122 (4.6)
1,154 (54.4)

93 (22.6)
160 (38.9)
148 (36.0)
10 (2.4)
137 (47.4)

.026

Table 2.4 Continued

Ever read BFRG

Data
available

Total
(N=3,535)

ZZ
(N=3,031)

SZ
(N=504)

Pvalue

3027

1,488 (49.2)

1,300 (49.6)

188 (46.3)

0.22

Comfortable with
Alpha1 knowledge
3438
<.001
a
No
167 (4.9)
119 (4.0)
48 (9.8)
a
Somewhat
1,513 (44.0) 1,244 (42.2) 269 (55.0)
1,758 (51.1) 1,586 (53.8) 172 (35.2)
Very a
Note: All statistics are reported as frequency (percentage) unless otherwise indicated.
a
denotes statistically significant difference based on post hoc analysis using standardized
residuals, BFRG- Big Fat Reference Guide, ADMAPP- Alphanet’s Disease Management
and Prevention Program
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Table 2.5 Results of adjusteda analyses comparing patients with SZ versus ZZ genotype
P-value
Rate Ratio
95% CI
Outcome
Parameter
b
Estimate (SE)
Frequency of pulmonary
0.20 (0.07)
0.0074
1.21
(1.05-1.40)
exacerbations in the past
yearc
Frequency of
0.21 (0.11)
0.0564
1.23
(0.99-1.52)
hospitalizations in the past
yeard
0.19 (0.04)
<.0001
1.21
(1.12-1.30)
Frequency of visits to a
primary care physician in
the past yearc
a
adjusted for age, gender, current smoking status, and CCI score, bParameter Estimate
(SE) for SZ genotype, cresults of negative binomial regression, dresults of zero-inflated
negative binomial regression
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Figure 2.1 Study sample flow diagram

26

CHAPTER 3.
THE BURDEN OF COUGH AND PHLEGM IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS WITHIN THE
COPD PATIENT-POWERED RESEARCH NETWORK (PPRN)
Abstract
Rationale: Cough and phlegm are common in patients with COPD and significantly
affect the quality of their day-to-day lives. The main objectives of this study were to
estimate the prevalence and assess the burden of cough and phlegm among patients with
a self-reported physician-diagnosed COPD, and to determine if an association is present
among reported levels of phlegm and cough, clinical outcomes and patients’ quality of
life.
Methods: Patient-reported data from the COPD Foundation’s Patient-Powered Research
Network (COPD PPRN) were used for this study. Severity of cough and phlegm were
assessed according to patients’ responses on COPD Assessment Test. Burden of cough
and phlegm on patients’ quality of life was evaluated using the Patient-Reported
Outcome Measurement Information System (PROMIS-29) instrument. Associations
between the seven domains of PROMIS-29 and the severity of cough and phlegm were
examined using MANOVAs. PROMIS-29 domain scores at follow-up were evaluated
stratified by changes in self-reported cough and phlegm severity levels between baseline
and follow-up.
Results: The average age of the study participants (n=5,286) was 64.4 years (SD=11.5),
95.3% white, 60.4% female, 51.2% married, and 42.2% had caregivers. Patients with
moderate/high cough (73.1%) or phlegm (67.9%) had significantly worse dyspnea
(p<.0001), greater number of exacerbations in the past 1 year (p<.0001), and worse
quality of life compared to those with no/low cough and phlegm. PROMIS-29 scores at
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follow-up were significantly associated with changes in cough and phlegm severity over
time.
Conclusions: In patients with COPD, severity of cough and phlegm were associated with
greater number of exacerbations, greater dyspnea, and worsened patient-reported quality
of life including physical and social functioning. Improvement in cough and phlegm
severity over time was associated with improvement of patient-reported quality of life.

3.1

Introduction
Chronic obstructive pulmonary disease (COPD) affects between 15 and 25

million adults in the United States (US), and is the fourth leading cause of death and the
second leading cause of disability.8,59,60 In the US, COPD is estimated to be responsible
for over 10 million physician office visits, 1.5 million emergency room department visits,
and approximately 700,000 hospitalizations annually.8,61 The direct and indirect cost
burden of COPD in the US are estimated at over $50 billion.8,62 Actual burden of COPD
is significantly higher considering that patients with COPD often have multiple comorbid
conditions.7
COPD assessment includes several criteria such as symptom burden, exacerbation
history, and airflow obstruction.8,63 The most recent Global initiative for chronic
Obstructive Lung Disease (GOLD) guidelines emphasizes focus on patients’ symptoms
in evaluating disease severity.63 Some of the most commonly reported symptoms of
COPD are cough, dyspnea, sputum production, and wheezing, which largely depend on
the stage of the disease. Cough, along with mucus production, is frequently among the
first reasons for seeking help from medical professionals among patients with COPD.64
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The association between COPD symptom severity and health-related quality of
life (HRQOL), including its physical, social function and psychological aspects, was
highlighted in published literature and attributed to the “humanistic” burden of the
disease.65 Additionally, the burden of nighttime COPD symptoms, especially cough and
production of mucus, on patients’ quality of life and sleep further contributes to increased
mortality and morbidity in this patient population.66 COPD symptom experience was
identified as closely related to patient health outcomes.67,68
However, little research has been conducted to specifically address patientreported burden of cough and phlegm on functional status, role fulfillment abilities and
impact on mood and sleep. Symptom severity perception as a subjective patient
experience is best evaluated using patient-reported data and patient-reported outcome
instruments.69
The main objectives of this study were to estimate the prevalence and assess the
burden of cough and phlegm among patients with a diagnosis of COPD within COPD
Foundation’s Patient-Powered Research Network (COPD PPRN) community, and to
determine if an association is present between reported levels of phlegm and cough,
clinical outcomes and patients’ quality of life. Secondary objectives of the study were to
evaluate associations between changes in cough and phlegm severity levels over time and
patients’ self-reported quality of life.
3.2

Methods
Our study used data from the patient-reported information collected by the COPD

PPRN. This secure online interactive patient registry maintained by the COPD
Foundation (COPDF) and funded by Patient-Centered Outcomes Research Institute
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(PCORI) and the COPDF, enrolls patients with self-reported physician diagnosed COPD
or risk factors for COPD. The COPD PPRN data used for the present study included only
individuals with a self-reported physician-diagnosed COPD, and excluded patients with
risk factors for but no diagnosis of COPD. Demographic information such as age, gender,
race, and ethnicity, COPD-related clinical information including COPD Assessment Test
(CAT) scores, frequency of exacerbations, dyspnea severity, as well as presence of
various comorbid conditions, smoking status, and other patient characteristics were
collected at the time of enrollment and completion of eConsent. Severity of symptoms,
burden of the disease and comorbidities as well as patient-reported outcomes are reported
for all patients at time of enrollment, and for a smaller subset of enrollees who have
completed baseline and follow-up surveys.
CAT was used to assess the frequency and severity of patients’ cough and
phlegm.70 CAT is a well-validated patient-completed questionnaire that measures eight
various symptoms of COPD (cough, phlegm, chest tightness, breathlessness going up
hills and stairs, activity limitation at home, confidence leaving home, sleep, and energy)
on a 0 - 5 point Likert-type scale.70 CAT was designed to assist health professionals in
quantifying burden of COPD symptoms on patients’ health status.71 Question 1 assesses
frequency of cough and is anchored by “I never cough” and “I cough all the time”
questions. Question 2 assesses severity of phlegm and is anchored by questions “I have
no phlegm (mucus) in my chest at all” and “My chest is completely full of phlegm
(mucus)” (Figure 3.1). Scoring range of CAT inclusive of all eight questions is 0-40 with
higher scores reflecting more severe burden of COPD symptoms. Suggested scoring
interpretation is low impact <10, moderate impact 10-20, high impact 21-30, and very
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high impact >30. Considering that our study is assessing the burden of only two COPD
symptoms, for the purposes of the present analyses, frequency and severity of cough and
phlegm levels were stratified into three categories according to the responses on
questions 1 and 2 of CAT: 1) 0-1 no/low, 2) 2-3 moderate and 3) 4-5 high. Additionally,
for some of the descriptive analyses, cough and phlegm severity levels were
dichotomized according to CAT scores of the respective components: 1) 0-1 no/low, and
b) 2-5 moderate/high. The joint effect across severity levels of cough and phlegm was
calculated and classified into four categories: 1) no or low cough/no or low phlegm, 2) no
or low cough/moderate or high phlegm, 3) moderate or high cough/no or low phlegm and
4) moderate or high cough/ moderate or high phlegm.
Modified Medical Research Council (mMRC) Dyspnea Scale items were
collected and used to measure functional impairment due to shortness of breath in
patients with COPD. mMRC rates patient-reported perception of dyspnea severity on a 04 Likert-type scale.72,73
Patient Reported Outcome Measurement Information System (PROMIS-29)
instrument was used to evaluate burden of cough and phlegm on patients’ quality of life
and specific functional abilities such as social and physical role functioning.74,75
Specifically, the PROMIS-29 profile instrument was designed to be used in people with
chronic conditions and encompasses 7 domains (Depression, Anxiety, Physical Function,
Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles
and Activities), with 4 questions for each domain.76,77 Data were collected at enrollment
and 12 months later at follow-up. Each of the questions had five response options scored
1-5. The total raw score of each domain ranged between 4 and 20 and was calculated as a
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sum of score values for each question. Scoring of the PROMIS-29 domains requires all
questions within a specific domain to be answered. Raw scores for each domain were
then converted to standardized T-scores with a mean of 50 (SD=10) using scoring tables
specific to each of the domains. Per PROMIS-29 scoring guidelines, for 5 out of 7
domains, a score of 50 represented the average for the general US population, and for
Ability to Participate in Social Roles and Activities, and Sleep Disturbance, a score of 50
represented the average of a calibration sample enriched for chronic morbidities.76 For
negatively worded concepts, such as Depression or Fatigue, higher PROMIS-29 T-score
(above 50) was worse as it represented more of the negative concept being measured.
Whereas, for positively worded concepts such as Ability to Participate in Social Roles
and Activities, higher PROMIS-29 T-score (above 50) was better.
Charlson Age-Comorbidity Index (CACI) was calculated using information on
self-reported illnesses to measure the burden of comorbidities. CACI is a validated tool
designed to predict patient outcomes according to age and comorbid conditions.78 It
incorporates 19 medical conditions weighted 1-6 points, and scores also receive an
additional point for every decade increase above the age of 50 years.
One year after completion of the baseline survey, patients were eligible to
participate in the follow-up survey. Among various follow-up characteristics of the
patients, data on CAT and PROMIS-29 scores were collected. PROMIS-29 follow-up
scores were computed and standardized according to the same scoring guidelines as
baseline scores. According to the changes in severity levels of cough and phlegm
between baseline and follow-up patients were stratified into four categories: 1) improved
- patients with moderate/high severity levels at baseline and no/low severity at follow-up;
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2) worsened - patients with no/low severity levels at baseline and moderate/high severity
at follow-up; 3) patients who maintained no/low severity at baseline and follow-up, 4)
patients who maintained moderate/high severity at baseline and follow-up.
Statistical Analyses
Descriptive statistics were computed and reported as mean (SD) for continuous
variables, and frequencies and proportions for categorical variables. Stratified analyses of
main demographic (age, gender, race/ethnicity, smoking status) and clinical
characteristics (CAT, mMRC, CACI, exacerbation frequency, 7 domains of PROMIS-29)
were performed by severity levels of cough and phlegm. Values between the strata were
compared using Chi-square tests for categorical variables and t-tests for continuous
variables. Correlations between cough and phlegm severity levels, and the correlation
between current cough and phlegm severity levels and presence or absence of cough or
phlegm for at least three months per year in the past two years were evaluated using
Kendall's tau-b. Standardized scores of PROMIS-29 domains were calculated and
reported as mean (SD) in the overall sample and stratified by cough and phlegm severity
levels.
Correlations between seven domains of PROMIS-29 were assessed using Pearson
correlation coefficients. Joint effect of severity of both symptoms was calculated across
cough and phlegm severity levels. One-way multivariate analysis of variance
(MANOVA)79 was conducted to identify mean differences between joint severity levels
of cough and phlegm and standardized scores of seven PROMIS-29 domains. Follow-up
ANOVAs and a series of post-hoc Fisher’s LSD tests were performed to examine
individual mean difference comparisons across all levels of the combined symptoms
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severity and all seven PROMIS-29 domains’ scores. Adjusted associations between
PROMIS-29 domains and severity levels of both cough and phlegm were evaluated
controlling for age, gender, and smoking history.
Associations between seven PROMIS-29 domain scores at follow-up and the four
categories of changes in cough and phlegm severity levels between baseline and followup were examined using MANOVA. Missing data analyses were performed to compare
select baseline characteristics of the patients included in the follow-up data analyses
versus those with missing follow-up data. The significance level was set at 0.05. All
statistical analyses were performed using SAS 9.4.
3.3

Results
Of the 5,314 respondents with self-reported physician-diagnosed COPD who

participated in the survey, 5,286 respondents had data to assess the severity of cough and
phlegm and were included in the baseline analyses (Figure 3.2). The majority of the
patients were women (60.4%) with a mean age of 64.4 years (SD=11.5), predominantly
white (87.9%), approximately half of them were married (51.2%), and 42.2% had
caregivers. Most of the respondents (88.2%) reported a history of ever smoking with an
average of 45.5 packs/year, and 17.8% of them were current smokers.
Moderate/high levels of cough were reported by 73.1% of the patients and
moderate/high levels of phlegm by 67.9% of the patients. Respondents with
moderate/high cough and phlegm severity were younger compared to those with no/low
levels of these symptoms (p<.0001). No statistically significant differences were found in
other demographic characteristics between the strata by cough or phlegm severity (Table
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3.1). A significantly greater proportion of patients with moderate/high levels of cough
(19.0%) and phlegm (19.8%) reported being current smokers compared to those with
no/low cough and phlegm (5.7% and 6.5%, respectively, p<.0001). Those with
moderate/high cough and phlegm had significantly worse self-reported dyspnea as
measured by mMRC (p<.0001), and greater number of exacerbations in the past 1 year
compared to those with no/low cough and phlegm (p<.0001). Four and greater
exacerbations per year were reported by 25.9% of patients with moderate to high cough
and 27.1% with moderate to high phlegm compared to those with no/low severity levels
of cough and phlegm (11.0% for both).
Cough and phlegm severity levels at baseline were strongly and positively
correlated with presence or absence of cough or phlegm for at least three months per year
in the past two years (τb = 0.607, p = 0.01). Among those respondents who reported
bringing up phlegm from their chest at least three months per year in the past 2 years
(68.5%), 87.1% had moderate/high phlegm levels. Similarly, of those who reported
having cough for at least three months per year in the past 2 years (63.1%), 92.7% had
moderate/high cough levels.
There was a strong, positive correlation between cough and phlegm levels as
measured by Kendall's tau-b, which was statistically significant (τb = 0.599, p < 0.01)
(Table 3.2). Joint effects of cough and phlegm severity levels were, therefore, an
appropriate measure of combining the severity of these two symptoms. Over 60% of the
patients had moderate to severe levels of both cough and phlegm (62.0%), and 21.1% had
no or low severity of both cough and phlegm. The remaining 16.9% of the study sample
had combinations of no/low and moderate/high levels of each of the symptoms.
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A total of 4,752 patients had complete data on all items in seven domains of
PROMIS-29 and were included in the analyses of quality of life. Analysis of missing data
(n=534, 10.1%) did not reveal any obvious patterns. Pearson correlations among the
seven domains of PROMIS-29 were significant (p<.0001) and ranged from r = -0.27 to
r = 0.77. The strongest correlations were identified between Physical Function and
Ability to Participate in Social Roles and Activities (r=0.77, p<.0001), Anxiety and
Depression (r=0.75, p<.0001), and Fatigue and Ability to participate in social roles and
activities (r=-0.67, p<.0001) (Table 3.3).
Mean scores of PROMIS-29 domains differed by levels of severity of cough and
phlegm (p<.0001) (Table 3.4). Figure 3.3 demonstrates the burden of severity of cough
and phlegm on patients’ quality of life in relation to the average scores for the general US
population within the seven domains of PROMIS-29 (mean=50, SD=10). Anxiety,
depression, fatigue, sleep disturbance, and pain interference scores increased in a
stepwise fashion as the severity levels of cough and phlegm increased from no/low to
moderate and high. Scores for these domains were on average one standard deviation
higher in patients with high cough and phlegm compared to the standard US population.
Similarly, scores for positively worded domains, such as Physical Function and Ability to
Participate in Social Roles and Activities decreased as the severity of cough and phlegm
increased. Patients with high levels of cough and phlegm scored on average 1 to 1.5
standard deviations lower on these domains compared to the average US population.
The results of the one-way multivariate analysis of variance (MANOVA)79
identified significant mean differences between the joint levels of cough and phlegm and
standardized scores of the seven PROMIS-29 domains (Pillai’s Trace=0.12, F (21,
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14232) =27.96, p<.0001). Follow-up one-way ANOVAs on each of the seven dependent
variables were performed, and all were found to be statistically significant (p<.0001). A
series of post-hoc tests (Fisher’s Least Significant Difference (LSD)) were conducted to
assess individual mean difference comparisons across the four levels of the joint cough
and phlegm severity levels and all seven PROMIS-29 domains. The results were
significant at the 0.0001 level except for no significant difference in Physical Functioning
and Social ability scores between groups with moderate to high levels of both cough and
phlegm and a group with low or no cough and moderate to high levels of phlegm.
Additionally, no significant difference in Anxiety, Depression and Fatigue scores were
found between no or low cough/moderate or high phlegm, and moderate or high cough/
no or low phlegm categories.
Adjusted association between severity levels of both cough and phlegm and
PROMIS-29 scores from all seven domains were significant controlling for age, gender
and smoking history (Pillai’s Trace=0.12, F (21, 13974) =26.91, p<.0001).
Overall, 2,696 participants qualified for the annual follow-up and 869 (32.2%) of
them completed the follow-up survey. Of those, 863 had data on cough and phlegm
severity, and 803 had complete data on PROMIS-29 and were included in the
longitudinal analysis. At baseline, the majority of these patients reported moderate/high
levels of cough and phlegm (66.9% and 64.4%, respectively), and only 33.1% and 35.6%
reported no or low levels of cough and phlegm, respectively. At follow-up survey
completion, 12.8-12.0% reported improved cough or phlegm and 9.3-10.2% reported
worsened cough or phlegm (Table 3.5). The majority of the patients continued having
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moderate/high levels of cough (54.1%) and phlegm (52.3%), and approximately a quarter
of the participants still had no/low cough (23.8%) or phlegm (25.4%).
Figure 3.4 demonstrates PROMIS-29 scores at follow up by severity changes in
cough and phlegm between baseline and follow-up in relation to the average scores for
the general US population within the seven domains of PROMIS-29 (mean=50,
(SD=10)). Patients who continued having moderate to high severity levels of cough and
phlegm reported having approximately half of a standard deviation greater scores for
anxiety, fatigue, depression, pain interference followed by patients whose levels
worsened from being no/low at baseline to moderate/high at follow-up. Scores for
physical function and social ability at follow-up were significantly lower for those who
continued having moderate to high severity levels of cough and phlegm and those whose
cough and phlegm worsened, compared to patients with lessened severity or remaining
with no/low cough and phlegm. Physical function scores were one standard deviation or
greater than average scores for US population among all severity levels.
PROMIS-29 domains scores at follow-up were significantly associated with
changes in cough and phlegm severity over time. The results of the one-way MANOVA
identified significant mean differences (one or more) between the cough severity changes
and standardized scores of the seven PROMIS-29 domains (Pillai’s Trace=0.16, F (21,
2385) =6.54, p<.0001). MANOVAs between the phlegm severity changes and seven
PROMIS-29 domain scores demonstrated similar results (Pillai’s Trace=0.09, F (21,
2385) =3.68, p<.0001). Follow-up one-way ANOVAs on each of the seven dependent
variables were found to be statistically significant (cough severity changes: p<.0001 for
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all domains, phlegm severity changes: p=0.0061 for depression, p<0.001 for anxiety and
p<.0001 for all other domains).
Missing data analyses compared select baseline characteristics of those patients
who qualified for one year follow-up and completed the survey (“responders”, n=869)
and those who qualified but did not respond to the invitation (“non-responders”,
n=1,827). The “responders” were on average three years older (64.7 years vs 61.5 years),
greater proportion of them were males (44.1% vs 32.2%, p<0.001), married (55.3% vs
49.7%, p<0.001), had college degree or higher (42.8% vs 32.1%), reported no or low
levels of phlegm (35.3% vs 30.7%, p=0.02) or cough (32.6% vs 25.6%, p<0.001).
Additionally, we compared select baseline characteristics of the participants included in
the follow-up analyses to those of the rest of the patients in the baseline cohort with
similar findings except for no significant difference in mean age.
3.4

Discussion
This study of the association between severity of cough and phlegm and patient-

reported outcomes in individuals within COPD PPRN community who self-reported
physician-diagnosed COPD yields several important findings. First, the burden of cough
and phlegm was high, with approximately three-quarters of the patients reporting
moderate to high levels of cough and/or phlegm. Our findings support previously
reported data on the frequency of cough (70%) and phlegm (60%) in patients with COPD
in a large international survey.64,80 Recent Global initiative for chronic Obstructive Lung
Disease (GOLD) statement acknowledged that cough and sputum production in the
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COPD population may be underreported.81 This further underlines the importance of
symptom burden estimates based on patient-reported data.
Previous research related to the burden of cough and phlegm on patients’ health
outcomes and their quality of life is limited.64 In earlier work, the major focus on cough
and phlegm was to define chronic bronchitis, which specifically uses frequent and
persistent cough and sputum production to define the phenotype.82-84 A pan-European
study highlighted the importance of patient-perceived daily variability of the symptoms
and related impact on quality of life and activities.85 The results of this study showed that
overall COPD symptoms are most troublesome in the mornings compared to other times
of the day. Specifically, among other symptoms, the greatest proportion of patients
reported morning difficulties with cough (60.1%) and phlegm (70.9%). Washing and
dressing were among the most affected by their symptoms morning activities reported by
the study participants (41.0% and 40.7% respectively). Moreover, other researchers
suggested that COPD patients with early-morning and nighttime symptoms are
significantly more likely to have worse HRQOL.82,86,87
Lindberg et al. in their recent work indicated that productive cough in patients
with COPD was associated with exacerbations and risk for death.88 Previous work also
identified cough to be significantly associated with decline in patients with airflow
obstruction and independently associated with disability in COPD.64 In a large
longitudinal study of Danish men, cough was found to have the highest predictive value
for subsequent hospitalization due to pulmonary disease, and for treatment for airflow
obstruction.89 Narrowing the focus to cough and phlegm particularly is important since
currently only a few pharmacotherapies directly address either of these symptoms.63,81
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In their recent narrative review, Miravitlles and Ribera described the impact of
COPD symptoms on disease burden and HRQOL of the patients.82 They highlighted the
association between burden of COPD symptoms and high levels of anxiety and
depression as well as greater risk of exacerbations and worse patient outcomes. However,
they did not specifically focus on cough and phlegm, and association between these
symptoms and patients’ functional status, and other various aspects of quality of life. Our
study findings indicate significant association between severity of cough and phlegm and
patient-reported quality of life as measured by PROMIS-29. In our study cohort,
increased cough and phlegm levels were associated with higher levels of fatigue, anxiety,
and depression, greater pain interference and sleep disturbance, and lower social abilities
and physical function.
The NIH-developed PROMIS-29 has been shown to be a valuable instrument to
assess several domains of quality of life across a range of chronic morbidities and various
clinical populations.77,90 In 2009, a longitudinal study assessed the validity of PROMIS
with COPD exacerbations, and evaluated responsiveness of the instrument with a known
change in the underlying COPD, i.e., acute and stable conditions.91 Recent study by Irwin
et al. examined the performance of PROMIS instrument in patients with COPD according
to their exacerbation status.92 It has identified that stable patients had significantly better
PROMIS scores in all domains. Similarly to our study, study by Irwin et al. used selfreported COPD status and did not include other clinical assessments.92
Findings of a multi-center cross-sectional study (CONCERT) supported the
validity of PROMIS in patients with COPD and identified that among all domains,
physical functioning was most negatively affected compared to the general population
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across all COPD severity grades.93 Consistent with these findings, our study results also
indicate the worst standardized scores in Physical Function (over 1 SD worse than the
average scores for the general US population) among all seven PROMIS-29 domains
across all cough and phlegm severity levels.
Recent research by Schalet et al. evaluated longitudinal performance of Physical
Function domain of PROMIS in six chronic health conditions including COPD.94 No
significant change in physical function over time was detected in patients with COPD
exacerbations which may be attributed to only minor improvements in physical function
during 12 weeks of follow-up and considerably small sample size of subgroups (under 20
patients).94 In the longitudinal portion of our study, patient-reported improvements in
cough and phlegm severity over time (improved scores on those questions in the CAT)
was associated with better quality of life at the follow-up timepoint as measured by
PROMIS-29.
The significance of patient-reported outcomes and particularly PROMIS-29 in
comparative effectiveness research was highlighted in the recent research by Craig et al.95
The authors identify the importance of patient-reported outcomes in assessing costeffectiveness of various treatment options.95 The findings of our study highlight the needs
to review and renew the search for therapies designed to reduce either cough or phlegm.
No new and effective cough medication has been developed by the pharmaceutical
industry in over a century.64 Only about a third of the patients in our study had either no
or low severity of cough or phlegm. Higher severity of cough and phlegm were found to
be associated with worse mood, pain, sleep, and physical and social functioning. The
levels of cough and phlegm might also be explored as a proxy for COPD disease severity.
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The consistent association between high levels of cough and phlegm burden and worse
quality of life suggests the need for further research in this area.
Strengths and Limitations
The main strengths of our study include a large number of patients enrolled in the
COPD PPRN as well as unique and rich data collected by the COPD PPRN. These data
include seldom-addressed patient-reported outcomes such as patient-perceived ability to
participate in social roles and activities, physical function, anxiety, depression, and sleep
disturbance. Some of the limitations of the study include potential selection bias in view
of the self-reported nature of physician-diagnosed COPD. Patient-reported clinical
information including presence of comorbidities, frequency of physician, ER visits and
hospitalizations are subject to potential recall bias. Also, classification of cough and
phlegm severity levels for the purposes of this study was performed according to the
respective CAT scores and is not a widely used classification. Additionally, many
participants were excluded from the follow-up analyses due to not qualifying, not
responding to the follow-up survey or missing data. Missing data analysis identified that
those included in the follow-up analyses differed from those excluded in several
demographic and clinical characteristics that may have introduced potential selection
bias.
3.5

Conclusion
In this population of people with self-reported physician-diagnosed COPD,

severity of cough and phlegm are associated with higher number of exacerbations, greater
dyspnea, and worsened patient-reported quality of life including physical and social
functioning. Improvement in cough and phlegm severity over time is associated with
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improvement of patient-reported quality of life. Further work in this area is needed
including exploration of new treatments aimed at improvement of cough and phlegm
severity in this patient population.
Funding Support: This study was funded through a Patient-Centered Outcomes
Research Institute® (PCORI®) Award (PPRN-1306-04748 Phase II) for the development
of the National Patient-Centered Clinical Research Network, known as PCORnet® and
through the COPD Foundation, Washington DC. The statements presented in this
publication are solely the responsibility of the authors and do not necessarily represent
the views of the Patient-Centered Outcomes Research Institute® (PCORI®), its Board of
Governors or Methodology Committee or other participants in PCORnet®.
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Table 3.1 Select demographic and clinical characteristics of the study participants, n = 5,286
Overall cohort
Phlegm Severity Levels

Cough Severity Levels

N=5,286

No/ Low
(CAT 0-1)
N = 1,699
(32.1%)

Moderate/ High
(CAT 2-5)
N= 3,587
(67.9%)

No/ Low
(CAT 0-1)
N = 1,424
(26.9%)

Moderate/ High
(CAT 2-5)
N = 3,862
(73.1%)

64.4 (11.4)
65 [57-72]

65.2 (11.3)‡
67 [59-73]

64.0 (11.5)‡
65 [57-72]

65.8 (11.1)†
67 [60-73]

63.8 (11.5)†
65 [57-72]

4,644 (87.9)
269 (5.1)
16 (0.3)
58 (1.1)
207 (3.9)
92 (1.7)

1,538 (90.5)
68 (4.0)
8 (0.5)
12 (0.7)
42 (2.5)
31 (1.8)

3,106 (86.6)
201 (5.6)
8 (0.2)
46 (1.3)
165 (4.6)
61 (1.7)

1,304 (91.6)
48 (3.4)
8 (0.6)
9 (0.6)
27 (1.9)
28 (2.0)

3,340 (86.4)
221 (5.7)
8 (0.2)
49 (1.3)
180 (4.7)
64 (1.7)

3,180 (60.4)
2,086 (39.6)

1,086 (64.2)
606 (35.8)

2,094 (58.6)
1480 (41.4)

848 (59.7)
572 (40.3)

2,332 (60.6)
1,514 (39.4)

Ethnicity, n (%)
Hispanic

141 (2.7)

48 (2.9)

93 (2.7)

34 (2.4)

107 (2.8)

BMI, mean (SD)

28.2 (7.6)

28.0 (7.1)

28.5 (7.7)

27.4 (6.7)

28.7 (7.8)

Never smoker, n (%)

620 (11.7)

230 (13.6)‡

390 (10.9)‡

153 (10.8)

467 (12.1)

Current smoker, n (%) †

815 (15.4)

110 (6.5)

705 (19.7 )

80 (5.7 )

735 (19.0 )

Age
Mean (SD)
Median [Q1-Q3]
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Race, n (%)
White
Black
Asian
Other*
Multiple races
Unknown/missing
Gender, n (%)
Female
Male

Table 3.1 Continued
Overall cohort

Phlegm Severity Levels

Cough Severity Levels
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N=5,286

No/ Low
(CAT 0-1)
N = 1,699
(32.1%)

Moderate/ High
(CAT 2-5)
N= 3,587
(67.9%)

No/ Low
(CAT 0-1)
N = 1,424
(26.9%)

Moderate/ High
(CAT 2-5)
N = 3,862
(73.1%)

Pack/year among ever
smokers
Mean (SD)
Median [Q1-Q3]

N=4,525
45.5 (28.3)
41 [25-62]

N=1,432
45.5 (28.0)
42 [25.5-62]

N=3,093
45.6 (28.4)
41 [24.5-63]

N=1,232
47.9 (28.6)‡
44 [27.9-66]

N=3,293
44.7 (28.2)‡
40 [24-61.5]

mMRC***, n (%)†
0
1
2
3
4

448 (8.5)
1,529 (29.2)
1,635 (31.2)
991 (18.9)
642 (12.2)

228 (13.6)
591 (35.2)
472 (28.1)
262 (15.6)
125 (7.5)

220 (6.2)
938 (26.3)
1,163 (32.6)
729 (20.4)
517 (14.5)

207 (14.7)
484 (34.3)
373 (26.4)
228 (16.2)
119 (8.4)

241 (6.3)
1,045 (27.3)
1,262 (32.9)
763 (19.9)
523 (13.6)

3.9 (2.3)

3.7 (2.0)

4.0 (2.4)

3.8 (1.8)

4.0 (2.4)

1,189 (22.8)
1,164 (22.4)
953 (18.3)
758 (14.6)
1,141 (21.9)

601 (36.0)
473 (28.3)
252 (15.1)
161 (9.6)
184 (11.0)

588 (16.6)
691 (19.6)
701 (19.8)
597 (16.9)
957 (27.1)

519 (37.3)
385 (27.6)
206 (14.8)
130 (9.3)
153 (11.0)

670 (17.6)
779 (20.4)
747 (19.6)
628 (16.5)
988 (25.9)

CACI
Mean (SD)
Exacerbations in the past
1 year**†, n (%)
0
1
2
3
4+
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N=5,286

No/ Low
(CAT 0-1)
N = 1,699
(32.1%)

Moderate/ High
(CAT 2-5)
N= 3,587
(67.9%)

No/ Low
(CAT 0-1)
N = 1,424
(26.9%)

Moderate/ High
(CAT 2-5)
N = 3,862
(73.1%)

History of cough for at
least 3 months per year for
the last 2 years†, n (%)
Yes
No

3,308 (63.1)
1,932 (36.9)

506 (30.0)
1,181 (70.0)

2,802 (78.9)
751 (21.1)

243 (17.2)
1,168 (82.8)

3,065 (90.1)
764 (20.0)

History of phlegm for at
least 3 months per year for
the last 2 years†, n (%)
Yes
No

3,564 (68.5)
1,638 (31.5)

459 (27.5)
1,211 (72.5)

Phlegm Severity Levels†, n
(%)
No/Low
Moderate/High

1,699 (32.1)
3,587 (67.9)

Cough Severity Levels†, n
(%)
No/Low
Moderate/High

1,424 (26.9)
3,862 (73.1)

1,114 (65.8)
585 (34.4)

3,105 (87.9)
427 (12.1)

310 (8.6)
3,277 (91.4)

475 (33.9)
925 (66.1)

3,089 (81.3)
713 (18.8)

1,114 ( 78.2)
310 ( 21.8)

585 (15.2)
3,277 (84.9)

Table 3.1 Continued
†p<0.0001; ‡p<0.001; *- Other races include Native Hawaiian/Pacific Islander and American Indian/ Alaska Native; **-defined as a
max number of antibiotic/prednisone/ER visit/ hospital, CACI- Charlson Age-Comorbidity Index, mMRC- (Modified Medical
Research Council) Dyspnea Scale
mMRC***:
0: "I only get breathless with strenuous exercise"
1: "I get short of breath when hurrying on the level or walking up a slight hill"
2: "I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my
own pace on the level"
3: "I stop for breath after walking about 100 yards or after a few minutes on the level"
4: "I am too breathless to leave the house" or "I am breathless when dressing or undressing"
48

Table 3.2 Cross-tabulation of cough and phlegm severity categories, n=5,286
Phlegm Categories
Cough Categories
High
Moderate
No/Low
High

708 (64.1)

498 (20.1)

48 (2.8)

Moderate

365 (33.0)

1,706 (68.7)

537 (31.6)

32 (2.9)

278 (11.2)

1,114 (65.6)

No/Low
Note: τb = 0.599, p < 0.01
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Table 3.3 Pearson correlations, means and standard deviations associated with the
PROMIS-29 domains, n=4,752
PF
SA
SD
AN
DE
FA
PI
Mean Stand.
Dev.
Physical
Function

1.0

Social
Ability

0.77

1.0

Sleep
Disturbance

-0.27

-0.36

1.0

Anxiety

-0.36

-0.47

0.43

1.0

Depression

-0.39

-0.51

0.41

0.75

1.0

Fatigue

-0.57

-0.67

0.50

0.54

0.59

1.0

Pain
Interference

-0.35

-0.43

0.43

0.42

0.42

0.51

1.0

37.14

7.33

42.78

9.13

52.55

8.88

56.10

10.34

54.66

10.09

57.11

9.79

54.33

10.83

Note: all correlations were statistically significant, p<.0001; PF-Physical Function; SASocial Ability; SD-Sleep Disturbance; AN- Anxiety; DE-depression; FA- Fatigue; PIPain Interference; Stand. Dev. - Standard Deviation;
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Table 3.4 PROMIS-29 T-scores in the overall sample and stratified by cough and phlegm severity levels at baseline, n=4,752
Phlegm Severity Levels
Cough Severity Levels
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Overall
(n=4,752)

No/Low
(CAT 0-1)
N =1,526
(32.1%)

Moderate
(CAT 2-3)
N=2,222
(46.8%)

High
(CAT 4-5)
N=1,004
(21.1%)

No/Low
(CAT 0-1)
N =1,282
(27.0%)

Moderate
(CAT 2-3)
N= 2,325
(48.9%)

High
(CAT 4-5)
N=1,145
(24.1%)

Physical Function

37.1 (7.3)

39.6 (8.2)

36.6 (6.7)

34.4 (6.0)

39.3 (8.3)

36.9 (7.0)

35.1 (6.2)

Ability to
Participate in Social
Roles and Activities

42.8 (9.1)

45.8 (9.9)

42.3 (8.4)

39.2 (7.9)

45.4 (10.0)

42.7 (8.7)

40.0 (8.0)

Sleep Disturbance

52.5 (8.9)

49.8 (8.6)

52.8 (8.5)

56.1 (8.7)

49.1 (8.5)

52.4 (8.3)

56.7 (8.8)

Anxiety

56.1 (10.3)

53.4 (10.0)

56.2 (10.2)

60.0 (10.0)

53.3 (9.9)

56.0 (10.0)

59.5 (10.5)

Depression

54.7 (10.1)

52.3 (9.7)

54.6 (9.7)

58.4 (10.3)

52.2 (9.7)

54.3 (9.7)

58.1 (10.4)

Fatigue

57.1 (9.8)

53.6 (10.0)

57.6 (9.1)

61.5 (8.9)

53.3 (10.2)

57.1 (8.9)

61.4 (9.4)

Pain Interference

54.3 (10.8)

51.2 (10.3)

54.7 (10.6)

58.1 (10.8)

50.3 (10.0)

54.4 (10.5)

58.6 (10.8)

Note: All statistics are reported as mean (SD) unless otherwise indicated. For negatively worded concepts -Sleep Disturbance,
Anxiety, Depression, Fatigue and Pain Interference- higher PROMIS-29 T-score (above 50) reflects worse outcome. For positively
worded concepts -Physical Function and Ability to Participate in Social Roles and Activities- higher PROMIS-29 T-score (above 50)
reflects better outcome.

Table 3.5 Changes in severity levels of cough and phlegm between baseline and followup, n=803
Cough
Phlegm
Improved (Mod/High to No/Low)

103 (12.8)

97 (12.1)

Remained Mod/High

434 (54.1)

420 (52.3)

Remained No/Low

191 (23.8)

204 (25.4)

75 (9.3)

82 (10.2)

Worsened (No/Low to Mod/High)
Note: All statistics are reported as n (%)
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Figure 3.1 Cough and phlegm CAT scales
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Figure 3.2 Study Flow Diagram
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Figure 3.3 PROMIS-29 T-scores at baseline by severity of cough and phlegm, n=4,752
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Note: PROMIS-29 T-scores above 50 (average for the US population) indicate worse outcomes for Anxiety,
Depression, Fatigue, Sleep Disturbance and Pain Interference, and better outcomes for Physical Function and
Social Ability.

Figure 3.4 . PROMIS-29 T-scores at follow-up by severity changes in cough and phlegm between baseline and follow-up, n=803
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Note: PROMIS-29 T-scores above 50 (average for the US population) indicate worse outcomes for Anxiety,
Depression, Fatigue, Sleep Disturbance and Pain Interference, and better outcomes for Physical Function and Social
Ability.

CHAPTER 4.
PSEUDOMONAS AERUGINOSA ASSOCIATED WITH SEVERITY
OF NON-CYSTIC FIBROSIS BRONCHIECTASIS MEASURED BY THE
BRONCHIECTASIS SEVERITY SCORE (BSI) AND THE FACED: THE US
BRONCHIECTASIS AND NTM RESEARCH REGISTRY (BRR) STUDY
Abstract
Rationale: Non-cystic fibrosis bronchiectasis (NCFB) is characterized by dilated
bronchi, poor mucus clearance and susceptibility to bacterial infection. Pseudomonas
aeruginosa (PA) is one of the most frequently isolated pathogens in patients with NCFB.
The purpose of the present study was to evaluate the association between presence of PA
and disease severity in patients with NCFB within the US Bronchiectasis and
Nontuberculous mycobacteria (NTM) Research Registry (BRR).
Methods: Baseline US BRR data from adult patients with NCFB collected between 2008
and 2018 was used for this study. Presence of PA was defined as one or more, and
chronic colonization as two or more positive PA cultures within two years prior to
enrollment. Descriptive statistics were computed for the overall study sample and
stratified by presence of PA. Values between the strata were compared using t-tests for
continuous variables, and Chi-square tests for categorical variables. Modified
Bronchiectasis Severity Index (m-BSI) and modified FACED (m-FACED) were
computed to evaluate severity of bronchiectasis. Unadjusted and multivariable
multinomial regression models were used to assess the association between presence of
PA and severity of bronchiectasis.
Results: Average age of the study participants (n=1,831) was 63.7 years (SD=14.1),
91.5% white, 78.8% female, 41.0% reported history of smoking, and 48.3% had history
of NTM. Presence of PA was identified in 25.4%, and chronic colonization in 13.6% of
the patients. Patients with presence of PA had significantly lower mean pre57

bronchodilator Forced Expiratory Volume in the first second (FEV1) % predicted
compared to those without PA (62.8% vs. 73.7%, p<.0001). In multivariate analyses,
patients in PA group had significantly greater odds for having high (ORadj=6.41 (95%CI:
4.15-9.89) and intermediate (ORadj=2.11 (95%CI: 1.40-3.16) severity vs. low severity on
m-BSI. The sensitivity analyses after excluding PA severity marker from calculation of
m-BSI and m-FACED showed the same direction of the association as in the main
analyses.
Conclusion: PA infection is common in patients with NCFB within the Bronchiectasis
and NTM Research Registry. Severity of bronchiectasis is significantly greater in patients
with PA which emphasizes high burden of the disease. Future longitudinal studies are
recommended to assess clinical outcomes and prognosis over time.

4.1

Introduction
Non-cystic fibrosis bronchiectasis (NCFB) is an etiologically diverse, irreversible,

and chronic disease associated with significant morbidity in adults.22,24 NCFB is
characterized by dilated bronchi, poor mucus clearance and susceptibility to bacterial
infection leading to productive cough, recurrent infections, and exacerbations.96,97
Prevalence of NCFB in the United States is increasing, especially with age, and has been
estimated between 230,000 and 430,000 cases using three large US healthcare
databases.98 Bronchiectasis was shown to be more expensive to treat compared to many
other chronic diseases.99 Annual burden of bronchiectasis to the healthcare system has
been estimated at approximately $630 million.97
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According to the “vicious circle” theory of bronchiectasis pathogenesis, airway
inflammation in response to pulmonary infection results in airway damage, mucus
collection, and further infections.24,79 Among the most prevalent gram-negative bacteria
responsible for pulmonary infections in patients with NCFB, Pseudomonas aeruginosa
(PA), an opportunistic pathogen, possesses natural resistance to antibiotics that makes
these infections particularly challenging to treat.100 PA colonization is associated with
worse lung function, higher mortality, hospitalizations, exacerbations, and decreased
quality of life.24,101 To date it remains unclear whether infection with PA is the result or
the cause of severe NCFB.102
The overall significance of PA in the natural course of bronchiectasis has been
reflected by inclusion of PA as a key marker in the calculation of several severity
assessment instruments. The Bronchiectasis Severity Index (BSI) is a disease-specific
clinical predictive tool derived in the United Kingdom and validated in several European
cohorts.25 This instrument was designed to identify bronchiectasis patients with future
risk for mortality, hospitalizations, exacerbations, and poor quality of life.25
Independently, Spanish researchers derived another severity assessment tool, FACED,
which utilizes only five dichotomized variables in its calculation and was validated for 5year mortality.26
A wide range of NCFB and PA management strategies exists among clinicians
both in the US and internationally, which highlights the need and importance of
collaborative research to improve patient outcomes.96 Findings from bronchiectasis
registry-based studies assist in guiding future clinical trials to enhance treatment options
in this patient population.
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The two main objectives of the present study were to estimate the prevalence of
PA and to evaluate the association between the PA and disease severity measured by the
bronchiectasis severity assessment instruments in patients with NCFB within the US
bronchiectasis registry.

4.2

Methods
This study used baseline data from the Bronchiectasis and NTM Research

Registry (BRR). The BRR is a centralized database of adult patients with physiciandiagnosed NCFB or NTM from 16 clinical institutions across the United States.103 After
obtaining informed consent, patients’ medical records are queried by trained site study
coordinators using standardized data collection forms. Data collection includes
demographic information, medical history and procedures, respiratory symptoms,
therapies and treatment, imaging, microbiology results, and other detailed clinical
information. Data entry is done through a centralized Internet-based entry system
managed by the data coordinating center. At the time of enrollment, patients with primary
Cystic Fibrosis bronchiectasis are excluded based on clinical history, previous sweat
chloride or genetic testing results. After enrollment, follow-up data is collected annually
from participants’ electronic medical records as it becomes available. As of October
2018, the BRR contained data on over 3,000 patients with up to 10 years of participant
follow-up. BRR obtains institutional review board (IRB) approvals for each BRR
participating site.
Baseline data utilized in the present study included data abstracted from patients’
records during the registry baseline period, which is defined as the interval between the
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two years prior to and 90 days after patients’ enrollment.103 Microbiological evaluation at
baseline consisted of a maximum of three respiratory culture results for each of the
bacterial, fungal and mycobacterial growth. Bacterial cultures included available data on
numerous microorganisms such as PA, Haemophilus influenza, Staphylococcus aureus,
and other pathogens. For the purposes of the present study, “presence” of a
microorganism was defined as one or more, and “chronic colonization” as two or more
positive cultures available at baseline. Patients with presence of PA at baseline were
identified as a “PA group,” and those without presence of PA at baseline as a “non-PA
group.” NTM status of patients in this study was defined as a reported history of NTMLD
prior to enrollment or one or more NTM positive cultures within the baseline period, or
both.103 Baseline data also contained information on number of hospital admissions and
exacerbations within the preceding two years prior to enrollment.
Severity of bronchiectasis was evaluated using the BSI, which was derived and
validated in the United Kingdom to identify bronchiectasis patients with future risk of
mortality, hospitalizations, exacerbations, and poor quality of life.25 The BSI is a
multidimensional instrument that consists of nine severity markers that have been
identified by the authors as common variables that predict mortality and
hospitalizations.25 These severity markers include age, BMI, Forced Expiratory Volume
in the first second (FEV1) % predicted, prior hospitalizations, history of exacerbations in
the previous year, Medical Research Council (MRC) dyspnea score, PA colonization,
colonization with other microorganisms, and radiological severity. For the purposes of
the present study, the BSI was modified according to the structure of the BRR data
collection, and modified BSI (m-BSI) was computed to evaluate the severity of NCFB.
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Specifically, modifications to the BSI were made to accommodate alternate measurement
of dyspnea in the BRR data collection forms that identifies presence or absence of
dyspnea when active or when at rest. The original BSI uses the MRC dyspnea scale that
rates patients’ perception of dyspnea severity on a 1-5 Likert-type scale.73,104 In addition,
BRR collects data on frequency of exacerbations and hospitalizations in the previous two
years at enrollment, and the BSI measures frequency of these markers in the past one year
(Table 4.2). Using the BSI scoring guidelines, the m-BSI (range 0-26 points) scores were
derived as sums of the score points for each of the nine severity markers. Using the same
guidelines, the patients were classified into three bronchiectasis severity categories
according to the total m-BSI score value: 1) low, 0-4 points, 2) intermediate, 5-8 points,
and 3) high, 9 or more points.
FACED, our second bronchiectasis severity assessment instrument, was derived
and validated by Spanish researchers independently from the BSI.26 It utilizes only five
dichotomized variables in the calculation the severity score- FEV1 % predicted, Age,
Chronic colonization, Extension (radiological), and Dyspnea. Similar to the BSI, this
instrument was also modified to accommodate the alternate dyspnea measurement scale
and modified FACED (m-FACED) was calculated for study participants (Table 4.3). The
m-FACED (range 0-7 points) was computed as a sum of the score points for each of the
five dichotomized variables. According to the FACED scoring guidelines, bronchiectasis
was classified into three severity classes according to the total m-FACED score: 1) mild,
0-2 points, 2) moderate, 3-4 points, and 3) severe, 5-7 points.
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Statistical Analyses
Descriptive statistics were computed for the overall study sample and stratified by
presence of PA at baseline. All results were reported as frequencies and proportions for
categorical variables, and as means (± SD) for continuous variables. m-BSI and mFACED severity levels were calculated for the overall cohort and analyzed stratified by
PA presence at baseline. Values between the strata were compared using t-tests for
continuous variables, and Chi-square tests for categorical variables. To assess the
influence of the variable identifying chronic colonization by PA on the severity of
bronchiectasis, m-BSI and m-FACED were also computed after excluding chronic
colonization by PA from the severity markers.
Ordinal regression models were initially considered for the analyses, but the
proportional odds assumption assessed using score test was found not to be supported by
the data for either m-BSI or m-FACED: m-BSI: χ2 (DF=6) = 43.46, p <.0001; m-FACED:
χ2 (DF=5) = 59.81, p <.0001). Thus, multinomial logistic regression models were used to
examine the association between presence of PA and severity categories of bronchiectasis
on m-BSI and m-FACED. Both unadjusted and adjusted results were obtained. In the
adjusted regression models, we controlled for variables that had clinical importance,
statistically significant difference between the PA groups in the bivariate analyses, and
either not included in the calculation of severity indices or used in a different form. The
final models included age as a continuous variable, gender, NTM status, and FEV1 %
predicted as a continuous variable.
Sensitivity analyses were performed by excluding the PA severity item from the m-BSI
and m-FACED scoring prior to fitting multinomial regression models. Cohen’s kappa
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statistic was used to measure the agreement between the m-BSI and FACED severity
classification. Missing data analyses compared the included study population with those
who were excluded from the analyses due to missing or incomplete data. Significance
level was set at 0.05. Statistical analyses were performed using SAS version 9.4.

4.3

Results
Of 3,008 participants in the BRR as of October 2018, 1,831 had data available on

variables needed for calculation of m-BSI and m-FACED and were included in the
present study. Demographic characteristics of the study population at baseline are
displayed in Table 4.1. The average age of the study participants was 63.7 years
(SD=14.1), 91.5% white, 78.8% female, 41.0% reported history of smoking. Presence of
PA was identified in 25.4%, and chronic colonization in 13.6%, of the patients.
Patients in the PA group had significantly lower mean pre-bronchodilator FEV1%
predicted (62.8% vs. 73.7%, p<.0001) and FVC% predicted (74.4% vs. 81.8%, p<.0001)
compared to those without PA. A significantly greater proportion of patients with
presence of PA at baseline reported three or more exacerbations (30.5%) and history of
hospital admissions (32.0%) in the previous two years prior to enrollment compared to
those without PA (17.2% and 17.1% respectively, p<.0001). Approximately half of the
respondents (48.3%) had a history of NTM with significantly greater proportion among
those in non-PA group (51.7% vs. 38.5%, p<.0001). There was no significant difference
in age, race, ethnicity or smoking history between the two groups.
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Tables 4.2 and 4.3 contain data on frequencies of individual components of mBSI and m-FACED in the overall study sample and stratified by PA group. Statistically
significant differences were found between the PA groups in age, FEV1% predicted,
hospital admissions, number of exacerbations, dyspnea, and radiological severity for mBSI (Table 4.2). Similarly, the two groups differed in FEV1% predicted, age, and
dyspnea for m-FACED (Table 4.3).
Table 4.4 demonstrates bronchiectasis severity categories using m-BSI and mFACED computed for the overall study sample and stratified by presence of PA at
baseline. According to m-BSI, a majority of the respondents were classified as
intermediate (41.2%) and high (35.5%) severity of bronchiectasis. In comparison, mFACED classified over half of the patients (52.5%) as mild disease severity, followed by
moderate (37.4%) and high severity (10.1%) of bronchiectasis. Table 4.5 demonstrates
comparison of bronchiectasis severity classification by both instruments and agreement
rates (kappa= 0.2632 (95% CI: 0.2334-0.2930)). There was fair agreement between the
two instruments in classifying severity of NCFB.105
For disease severity, a significantly greater proportion of patients with PA were
classified as having high severity of bronchiectasis using both m-BSI (60.9% vs. 26.9%,
p<.0001) and m-FACED (25.8% vs. 4.8%, p<.0001) compared to those without PA.
Likewise, both m-BSI and m-FACED classified greater proportion of patients without PA
as having low and mild severity of the disease (m-BSI: 27.9% vs. 9.7%, m-FACED:
58.9% vs. 33.8%, p<.0001) (Figure 1).
Table 4.4 presents the results of the sensitivity analyses demonstrating the
distribution of the m-BSI and m-FACED severity categories after excluding PA severity
65

marker from the scores’ calculations. Removing chronic colonization by PA variable, that
is weighted as 3 points in the calculation of the m-BSI and 1 point in m-FACED, resulted
in a greater proportion of the participants to be re-classified as low or moderate severity
by m-BSI and m-FACED. We compared disease severity between the PA strata after
removing PA variable from the scores’ calculations. The proportion of PA-positive
patients who were classified as high severity of bronchiectasis on m-BSI and FACED
remained significantly greater compared to those without PA (m-BSI: 45.8% vs. 26.9%,
p<.0001; m-FACED: 11.8% vs. 4.8%, p<.0001).
Results of the unadjusted and adjusted multinomial regression models are
presented in Table 4.6. The multinomial regression estimated the log-odds: 1) comparing
high severity of bronchiectasis vs low, and 2) comparing intermediate severity vs low.
First, we fit the unadjusted multinomial regression model with m-BSI as an outcome
variable. Patients in PA group had 6.53 times the odds for having high severity vs. low
(95% CI: 4.62-9.23), and 1.88 times the odds for having intermediate severity vs. low
(95% CI: 1.31-2.69).
The adjusted multinomial regression fit the two equations below, with each
comparison having its own intercept and set of coefficients:
1) Log (

ሺ୷ୀୌ୧୦ሻ
ሺ୷ୀ୭୵ሻ

) = β0 + β1 (PA =1) + β2 (Age)+ β3(Female=1) + β4 (FEV1%predicted)+

β5 (Exacerbations in the past 2 years=1) + β6 (NTM history=1)

2) Log (

ሺ୷ୀ୍୬୲ୣ୫ୣୢ୧ୟ୲ୣሻ
ሺ୷ୀ୭୵ሻ

) = β0* + β1* (PA =1) + β2* (Age)+ β3* (Female=1) + β4*

(FEV1%predicted)+ β5* (Exacerbations in the past 2 years=1) + β6* (NTM history=1)
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Results of the adjusted multinomial regression model are presented in Table 4.6.
Controlling for other covariates in the model, participants in PA group had 6.15 times the
odds of being classified as high severity of bronchiectasis versus low severity on m-BSI
(95% CI 3.98-9.50), and 2.06 times the odds of being classified as intermediate severity
of bronchiectasis versus low severity on m-BSI (95% CI 1.37-3.09).
Similarly, we found a significant association between presence of PA at baseline
and severity of bronchiectasis calculated using m-FACED. Table 4.6 presents the results
of unadjusted and adjusted multinomial regressions using m-FACED as an outcome
variable. In unadjusted analyses, participants with PA had 9.47 times the odds (95% CI:
6.69-13.39) for having severe bronchiectasis on m-FACED versus mild, and 1.94 times
the odds (95% CI: 1.53-2.47) for having moderate bronchiectasis vs. mild.
Results of the adjusted analyses demonstrated that controlling for other covariates
in the model, the participants with PA had 14.59 times the odds (95% CI: 8.53-24.94) for
having severe bronchiectasis versus low, and 2.15 times the odds (95% CI: 1.59-2.91) for
having moderate bronchiectasis vs. mild.
Results of the sensitivity analyses after excluding PA severity marker from
calculation of m-BSI and m-FACED showed the same direction of the association as in
the main analyses, although the effect size was attenuated in unadjusted analyses and
failed to reach statistical significance at α=0.05 in most adjusted analyses for both m-BSI
and m-FACED (Table 4.6).
Missing data analyses did not reveal any significant differences between the
patients included in the present study and those excluded from the analyses due to
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incomplete data in gender, ethnicity, and smoking status. However, we identified a
greater proportion of white patients among those included in the study (91.53% vs.
88.81%, p=0.02). In addition, our study participants were on average over two years
younger (63.7 vs. 66.0 years, p<.0001), and had lower FEV1%predicted (70.9 (±22.2) vs.
77.7 (±21.6), p<.0001) and FVC % predicted (79.9 (±19.7) vs. 87.6 (±20.2), p<.0001)
compared to excluded patients.
4.4

Discussion
Our study of patients with NCFB utilizes baseline data from the BRR (n=1831) to

assess the prevalence of PA presence in sputum of patients with NCFB and evaluates the
association between the presence of PA and disease severity using two bronchiectasis
severity assessment instruments.
Our analyses indicate that over a quarter of patients in our study (25.4%) showed
presence of PA in their sputum culture at baseline, and 13.6 % of the participants had
chronic colonization by PA. This is in agreement with previously reported PA prevalence
in the earlier BRR cohort103 as well as other studies of patients with NCFB including a
Spanish cohort with 19.7% of patients with chronic PA colonization.106 Our findings also
support the recent report of chronic PA infection in 15% of patients within the European
FRIENDS bronchiectasis cohort.107 Notably, the lower prevalence of PA presence of only
12% was reported by researchers in a longitudinal study in Australia.108 Significantly
higher prevalence of PA presence (47%) and colonization (30%) were reported by
authors of a recent study in England.109 The authors suggest that the high prevalence of
PA among their patients might be attributed to longer follow-up periods or crossinfection.109
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Our review of reported PA prevalence in various bronchiectasis cohorts reflects a
wide variety of prevalence estimates of presence as well as chronic colonization of PA in
patients with NCFB in different geographic areas. In some cohorts, including our study
population, PA is identified as the most prevalent microorganism103 while others report
Haemophilus influenza was the most prevalent pathogen.108,110 Identification of prevalent
microorganisms and treatment selection according to the culture results is highly
important in patients with NCFB. According to the vicious cycle hypothesis, pathogenic
microorganisms such as PA may potentially play a role in the development of
bronchiectasis.24,79 Hence, early identification of PA presence and prevention when
possible as well as the timely start of appropriate antibacterial therapy are highly
recommended in patients with bronchiectasis.111
We observed that almost a third of the patients in the PA group reported having
three or more exacerbations in the past two years compared to only 17.1% of those
without presence of PA. Similar finding have been previously reported in the European
cohort of patients with bronchiectasis by Chalmers et al.112 In their recently published
research, the authors identified that patients with chronic PA infection had over two times
the odds for having three or more exacerbations at follow-up even when they had less
than three exacerbations at baseline. Rogers et al. in their recent study highlighted that
presence of PA in sputum of patients with bronchiectasis was the best predictor of future
exacerbations.113 Chalmers et al. established a “frequent exacerbator phenotype” among
patients with NCFB that reflects that prior exacerbations in these patients predict future
risk for exacerbations.112 Considering that exacerbations are frequently associated with
bacterial infections, and PA is one of the most prevalent microorganisms in patients with
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NCFB, it is critical to recognize the importance of timely identification of PA in sputum
which has important management and prognostic implications in this patient
population.24,114
Our study findings indicate that patients with presence of PA have worse
pulmonary function compared to those without. This supports earlier research by Evans
et al. that chronic colonization by PA is associated with worse lung function including
lower FEV1 and FVC %predicted than in patients without PA.102 The authors suggest
that PA colonization takes place in patients with already rapidly declining lung function
and additionally accelerates the decline.102 This agrees with another study by Davies et al.
that PA infection occurs in patients with more severely impaired lung function, however,
PA colonization does not influence the rate of decline in pulmonary function over time.115
Consistent with previous research, our study results suggest that the presence of
PA infection in patients with NCFB is associated with high severity of disease and poor
prognosis.24,102,116 Until recently, there were no bronchiectasis-specific severity
assessment instruments that would assist in stratifying the risk for mortality,
exacerbations, hospitalizations, and quality of life. Chalmers and colleagues derived and
validated the BSI to identify high-risk patients with bronchiectasis and guide appropriate
therapy and disease management options.25 A significantly greater proportion of patients
with PA in our study were classified as high severity of disease on m-BSI compared to
those without PA. We observed similar results using another bronchiectasis-specific tool,
m-FACED, to stratify disease severity by PA presence. Of note, even presence of only
one or more positive PA cultures in our study population was significantly associated
with disease severity classification that utilizes PA chronic colonization as a predictor.
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This suggests that patients with even only presence of PA may have considerably greater
risks for poor prognosis.
Our findings of fair agreement (kappa= 0.2632) between the m-BSI and mFACED in classifying the severity of NCFB support findings by researchers in Portugal.
A study by Costa et al. compared the performance of the BSI and FACED and found a
similar association between the scores (kappa=0.330, p=0.002).117
Rosales-Mayor et al. recently compared the performance of the BSI and FACED
within a Spanish cohort of patients with bronchiectasis, and concluded that these
prognostic scores classified patients differently.118 The majority of patients in their study
were classified as severe (54.4%) and moderate (25.8%) on BSI, and as mild (59.3%) and
moderate (33.5%) on FACED. The authors highlighted that the BSI showed superior
ability to predict future exacerbations within their cohort of patients compared to
FACED, and suggested modifications to enhance the existing FACED by including an
exacerbation severity marker.118 Similar to the research by Rosales-Mayor et al.118, our
findings indicate that even after modifications made to the original instruments, m-BSI
and m-FACED categorize severity of bronchiectasis in patients with NCFB differently,
and distribution of severity categories in our study population is similar to the findings by
Rosales-Mayor and colleagues. In our study, m-BSI stratified significantly higher number
of patients into high severity group compared to m-FACED which suggests worse
prognosis and high risk for poor outcomes. This might be related to the fact that FACED
does not account for the number of exacerbations, a known important factor in
identifying a future risk of the patients with NCFB. FACED has been validated for 5-year
all-cause mortality risk and has not been validated for exacerbations.26
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Wilson et al. showed that health-related quality of life (QoL) of patients with PA
colonization was significantly worse compared to those with no PA using several
standardized measures.116 Patients with PA in their study also had worse pulmonary
function and greater disease severity on CT scans, although the authors suggest that
exacerbation frequency and bacteriology were better correlates to QoL. The authors also
highlighted the importance of breaking down the non-PA group into subcategories by the
presence of other microorganisms.116 The QoL measures were not available in our data,
although our study assessed and compared shortness of breath between the PA groups. A
significantly greater proportion of patients with PA presence reported dyspnea when
active and when at rest which may worsen their quality of life.
High severity classification of patients with PA in our study suggest the
importance of appropriate management considerations to improve prognosis in this
patient population. Wilson and colleagues in their recent work highlighted the challenges
associated with the treatment of NCFB patients with presence of PA.96 The most recent
British Thoracic Society (BTS) guidelines for bronchiectasis in adults recommend using
the BSI to help guide management of patients.119 Their updated stepwise management
recommendations consider the underlying cause of NCFB and exacerbation frequency in
treatment considerations. Wilson et al. underline the opportunities for PA management in
patients with NCFB during the three timepoints: at first isolation, during exacerbations,
and chronic PA colonization.96 The authors reflect on the importance of international
collaborations in research into management strategies and development of new drugs for
patients with this chronic disease, a discussion that took place during an expert forum
held at the ERS in 2014.96 Renewed interest in NCFB, increase in research activity within
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international bronchiectasis registries and needs for multidisciplinary approach to
management of NCFB to improve patient outcomes were also highlighted at the recent
World Bronchiectasis Conferences.23
Strengths and Limitations
Among the strengths of the present study, it is important to note the large number
of patients with NCFB and NTMLD enrolled in the US BRR, as well as the exceptionally
wide range of detailed data collected on clinical characteristics of the BRR cohort and
patient outcomes.
As with any registry-based observational study, our study has some limitations.
The BRR participants are recruited from the tertiary referral institutions and may not be
representative of the general population of patients with NCFB. Additionally, considering
the high interest of these institutions in NTMLD, our study cohort may be enriched for
patients with NTM. Geographic distribution of the referral medical facilities mainly
represents large cities in the Eastern part of the US, which may have introduced a
selection bias.
The BRR contains data collected from multiple study sites. Our study did not
account for potential differences in patient characteristics, the prevalence of
microorganisms or comorbidities, or physician practices and treatment availabilities
across the medical institutions. Also, patients within clinical sites might be similar and
more correlated in their characteristics.
Clinical data obtained using medical charts abstraction is often subject to
recording errors and missing entries which may lead to reporting and non-response
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biases. Although, the data management system has incorporated expected range checks to
lessen potential data entry errors, and all study coordinators utilized the same
standardized data collection forms.
Another potential limitation is that our study modified the bronchiectasis severity
scores to adapt to the BRR data collection. Although, the modifications were relatively
minor and mainly related to a measure of dyspnea and time period of exacerbations and
hospitalization frequencies. In addition, potential selection bias due to missing and
incomplete data cannot be excluded.
4.5

Conclusion
PA infection is common in patients with NCFB within the BRR. The severity of

bronchiectasis is significantly greater in patients with PA which emphasizes the high
burden of the disease. Future longitudinal studies are recommended to assess clinical
outcomes and prognosis over time. Further collaborative work in this area are needed
including exploration of new management options aimed at the improvement of patient
outcomes and prognosis in PA infected NCFB patients.
Funding support: This study was sponsored by the COPD Foundation
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Table 4.1 Select baseline characteristics of the study population within the BRR
stratified by presence of PA*, n=1,831
Overall
Presence of PA*
No Presence of
N=1,831
N=465 (25.4%)
PA
N=1,366
(74.6%)
Age, years, mean (SD)
63.7 (14.1)
64.4 (14.8)
63.5 (13.9)
Female, n (%) †

1,443 (78.8)

350 (75.3)

1,093 (80.0)

Race, n (%)
White
Black or African-American
Asian
Other**

1,676 (91.5)
46 (2.5)
52 (2.8)
57 (3.1)

424 (91.2)
9 (1.9)
13 (2.8)
19 (4.1)

1,252 (91.7)
37 (2.7)
39 (2.9)
38 (2.8)

82 (4.5)

27 (5.8)

55 (4.0)

Smoking history, n (%)
Current
Former
Never
NTM-positive***, n (%) ‡

28 (1.5)
718 (39.5)
1,072 (59.0)
885 (48.3)

2 (0.4)
184 (39.9)
275 (59.7)
179 (38.5)

26 (1.9)
534 (39.4)
798 (58.7)
706 (51.7)

Pre-bronchodilator FEV1
%predicted, mean (SD) ‡

70.9 (22.2)

62.8 (21.3)

73.7 (21.8)

Pre-bronchodilator FVC
%predicted, mean (SD) ‡

79.9 (19.7)

74.4 (19.7)

81.8 (19.4)

377 (20.6)

142 (30.5)

235 (17.2)

Hispanic, n (%)

Three or more
exacerbations within the
past 2 years, n (%) ‡

History of hospital
384 (21.0)
149 (32.0)
235 (17.1)
admissions within the past
2 years, n (%) ‡
BRR- Bronchiectasis Research Registry; PA- Pseudomonas aeruginosa; NTM Nontuberculous mycobacteria; FEV1- Forced Expiratory Volume in the first second;
FVC- Forced vital capacity; *≥1cultures positive for PA at baseline, ** includes Native
Hawaiian or Other Pacific Islander and American Indian or Alaska Native; ***- history
of NTM or ≥1 cultures positive for NTM at baseline; †p<0.05, ‡p<0.0001
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Table 4.2 m-BSI severity markers distribution in the overall study sample and stratified
by PA presence, n=1,831
Severity Markers
Score
Overall
Presence of
No Presence
pN=1,831
Points
PA*
of PA
value
N=465
N=1,366
(25.4%)
(74.6%)
Age
<50
0
261 (14.25)
75 (16.13)
186 (13.62)
0.0053
50-69
2
862 (47.08)
187 (40.22)
675 (49.41)
70-79
4
533 (29.11)
148 (31.83)
385 (28.18)
80+
6
175 (9.56)
55 (11.83)
120 (8.78)
BMI
≥ 18.5
0
1,601 (87.44) 409 (87.96)
1,192 (87.26) 0.6961
<18.5
2
230 (12.56)
56 (12.04)
174 (12.74)
FEV1% Predicted
>80
0
648 (35.39)
100 (21.51)
548 (40.12)
<.0001
50-80
1
851 (46.48)
225 (48.39)
626 (45.83)
30-49
2
271 (14.80)
121 (26.02)
150 (10.98)
<30
3
61 (3.33)
19 (4.09)
42 (3.07)
Hospital
admissions in
0
1,447 (79.41) 316 (67.96)
1,131 (82.80) <.0001
previous 2 years†*
No
5
384 (20.97)
149 (32.04)
235 (17.20)
Yes
Number of
exacerbations in
previous 2 years†*
1,131 (82.80) <.0001
1,454 (79.41) 323 (69.46)
0
<3
235 (17.20)
142 (30.54)
2
377 (20.59)
≥3
Dyspnea†**
164 (35.27)
0
748 (40.85)
No reported
584 (42.75)
0.0119
Dyspnea (shortness
of breath)
759 (41.55)
2
Dyspnea (shortness
205 (44.09)
554 (40.56)
of breath) when
active
3
324 (17.70)
Dyspnea (shortness
96 (20.65)
228 (16.69)
of breath) when at
rest
PA Colonization
No
0
1,582 (86.40) 216 (46.45) 1,366 (100.00) <.0001
Yes
3
249 (13.60)
249 (53.55)
--

76

Table 4.2 Continued
Severity Markers
Score
Points

Overall
N=1,831

Presence of
PA*
N=465
(25.4%)

No Presence
of PA
N=1,366
(74.6%)

pvalue

Colonization with
other organisms
No
0
1,734 (94.70) 440 (94.62) 1,294 (94.73) 0.9301
Yes
1
97 (5.30)
25 (5.38)
72 (5.27)
Radiological
Severity
<3 lobes involved
1,005 (54.89) 238 (51.18)
767 (56.15) 0.0630
≥3 lobes involved or
0
cystic bronchiectasis
1
826 (45.11)
227 (48.82)
599 (43.85)
m-BSI –modified Bronchiectasis Severity Index; BMI- Body Mass Index; FEV1- Forced
Expiratory Volume in the first second; PA- Pseudomonas aeruginosa; †indicates
modified variables. *Original variable in the BSI includes frequency in the previous 1
year.
**Original Dyspnea variable included in the BSI is categorized according to Medical
Research Council (MRC) scale: 1-3 (0 points), 4 (2 points), 5 (3 points):
MRC: 1 – Not troubled by breathlessness except on strenuous exercise
2 - Short of breath when hurrying on the level or walking up a slight hill
3 – Walks slower than most people on the level, stops after a mile or so, or stops after 15
minutes walking at own pace
4 – Stops for breath after walking about 100 yards or after a few minutes on level ground
5 - Too breathless to leave the house, or breathless when undressing
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Table 4.3 m-FACED severity markers distribution in the overall study sample and
stratified by PA presence, n=1,831
Dichotomized
Score
Overall
Presence of
No Presence
pN=1,831
Variables
Point
PA*
of PA
value
N=465
N=1,366
s
(25.4%)
(74.6%)
F-FEV1% Predicted
≥50%
0
1,499 (81.87)
325 (69.89)
1,174 (85.94) <.0001
<50%
2
332 (18.13)
140 (30.11)
192 (14.06)
A- Age
<70 years
≥70 years

0
2

1,123 (61.33)
708 (38.67)

262 (56.34)
203 (43.66)

861 (63.03)
505 (36.97)

0.0105

C- Chronic
Colonization by PA
No
Yes

0
1

1,582 (86.40)
249 (13.60)

216 (46.45)
249 (53.55)

1,366 (100.00)
--

<.0001

E- Extension
≤ 2 lobes affected
> 2 lobes affected

0
1

516 (28.18)
1,315 (71.82)

129 (27.74)
336 (72.26)

387 (28.33)
979 (71.67)

0.8074

D- Dyspnea†*
0.0029
568 (41.58)
725 (39.60)
157 (33.76)
No reported Dyspnea
0
(shortness of breath)
Dyspnea (shortness
798 (58.42)
1,106 (60.40)
308 (66.24)
1
of breath) when
active and/or when at
rest
m-FACED- modified FACED; PA- Pseudomonas aeruginosa; FEV1- Forced Expiratory
Volume in the first second; † indicates modified variables. * Original Dyspnea variable
included in FACED is dichotomized according to modified Medical Research Council
(mMRC) scale: 0-2 (0 points); 3-4 on mMRC scale (1 point):
0-Dyspnea only with strenuous exercise
1 - Dyspnea when hurrying or walking up a slight hill
2 – Walks slower than people of the same age because of dyspnea or has to stop for
breath walking at own pace
3 – Stops for breath after walking 100 yards or after a few minutes
4 - Too dyspneic to leave house or breathless when undressing

78

Table 4.4 Severity of bronchiectasis by m-BSI and m-FACED in the overall study sample and stratified by presence of PA* at
baseline including and excluding PA from the severity scores calculation, n=1831
Overall
Presence of
No Presence
Overall
Presence of No Presence
N=1831
N=1,831
PA
PA
of PA
of PA
N=465
N=1,366
N=465
N=1,366
(25.4%)
(74.6%)
(25.4%)
(74.6%)
(PA included in severity scores calculation)
(PA excluded from severity scores
calculation)
m-BSI severity categories, n (%)
Low
Intermediate
High

426 (23.3)
755 (41.2)
650 (35.5)

45 (9.7)
137 (29.5)
283 (60.9)

381 (27.9)
618 (45.2)
367 (26.9)

460 (25.1)
791 (43.2)
580 (31.7)

79 (17.0)
173 (37.2)
213 (45.8)

381 (27.9)
618 (45.2)
367 (26.9)
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m-FACED severity categories, n (%)
962 (52.5)
157 (33.8)
805 (58.9)
1008 (55.1)
203 (43.7)
805 (58.9)
Mild
684 (37.4)
188 (40.4)
496 (36.3)
703 (38.4)
207 (44.5)
496 (36.3)
Moderate
185 (10.1)
120 (25.8)
65 (4.8)
120 (6.6)
55 (11.8)
65 (4.8)
Severe
m-BSI –modified Bronchiectasis Severity Index; m-FACED- modified FACED; PA- Pseudomonas aeruginosa; *- ≥1cultures positive
for PA at baseline;

Table 4.5 Classification of bronchiectasis severity by m-BSI versus m-FACED, n=1831
m-FACED
m-BSI

Mild
(n=962)
395

Moderate
(n=684)
31

Severe
(n=185)
0

Intermediate (n=755)

414

332

9

High (n=650)

153

321

176

Low (n=426)

Note: all data are shown as n; Kappa= 0.2632; m-BSI –modified Bronchiectasis Severity
Index; m-FACED- modified FACED;
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Table 4.6 Results of the unadjusted and adjusted multinomial logistic regressions for outcomes m-BSI and m-FACED including and
excluding PA from the severity scores calculation, n=1,831
ORunadj (95% CI)
ORadj (95% CI)*
ORunadj (95% CI)
ORadj (95% CI)*
(PA included in severity scores
calculation)

(PA excluded from severity scores
calculation)

m-BSI
PA presence
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High severity vs Low

6.53 (4.62-9.23)

6.15 (3.98-9.50)

2.80 (2.08-3.76)

1.56 (1.06-2.29)

Intermediate severity vs Low

1.88 (1.31-2.69)

2.06 (1.37-3.09)

1.35 (1.01-1.81)

1.12 (0.80-1.58)

Severe vs Mild

9.47 (6.69-13.39)

14.59 (8.53-24.94)

3.36 (2.27-4.96)

1.72 (0.84-3.54)

Moderate vs Mild

1.94 (1.53-2.47)

2.15 (1.59-2.91)

1.66 (1.32-2.07)

1.19 (0.89-1.59)

m-FACED
PA presence

m-BSI –modified Bronchiectasis Severity Index; m-FACED- modified FACED; PA- Pseudomonas aeruginosa; OR- Odds Ratio; CIConfidence Interval; FEV1- Forced Expiratory Volume in the first second; * Adjusted for age, gender, baseline FEV1% predicted,
NTM status and history of exacerbations in the past 2 years;

Figure 4.1 Distribution of m-BSI and m-FACED categories in the overall cohort and
stratified by PA presence, n=1,831

m-BSI- modified Bronchiectasis Severity Index; m-FACED- modified FACED; PAPseudomonas aeruginosa;
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CHAPTER 5. CONCLUSION
5.1

Summary
The purpose of this dissertation research was to enhance the body of literature

with new findings on symptom burden, disease severity and health-related behaviors in
three chronic pulmonary diseases. This research utilized data from three different diseasespecific registries to conduct the analyses: 1) patients with Alpha1-Antitrypsin deficiency
(AATD) enrolled in AlphaNet’s Disease Management And Prevention Program
(ADMAPP); 2) COPD Foundation’s Patient-Powered Research Network (COPD PPRN)
data on patients with a self-reported physician-diagnosed Chronic Pulmonary Obstructive
Disease (COPD); and 3) the Bronchiectasis and NTM Research Registry (BRR) data
collected from multiple US clinical sites on patients with Non-Cystic Fibrosis
Bronchiectasis (NCFB) and Nontuberculous mycobacteria (NTM).
Chapter Two of this research compared health and behavioral characteristics in
patients with ZZ and SZ genotypes of AATD within ADMAPP to recognize the differing
needs in health education and behavioral intervention between the two AATD
genotypes.27 The findings demonstrated that individuals with SZ genotype had more
frequent exacerbations as well as greater number of hospitalizations and physician visits
compared to patients with more deficient ZZ genotype. These findings may be related to
higher prior exposure of SZs to smoking and lower adherence to the recommendations of
ADMAPP. SZs reported longer and heavier prior smoking history, and a greater
proportion of them were current smokers. In addition, SZs had worse perception of their
health, fitness and other health-related behaviors. Possible explanations may include that
the perception of a lower disease risk in SZs may be associated with poor adherence to
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healthy lifestyle recommendations of ADMAPP and considerably worse health status
compared to more severely deficient ZZs.27 Of note, SZs in this study sample had
significantly more comorbid conditions including hypertension, cerebrovascular disease,
and were on average two years older than individuals with ZZ genotype. Also, SZs
reported being less comfortable with their knowledge about the disease compared to ZZs.
The lower adherence to ADMAPP and lack of knowledge about their condition, as well
as poor health-related behavior choices, could be related to the self-perceived low
seriousness of the disease in individuals with SZ genotype. Our study suggests that more
severely AAT deficient ZZs are more adherent to disease management recommendations
and maintain healthier lifestyles even though their condition is considered more severe.
Chapter Three of this research estimated the patient-reported prevalence of
moderate to severe cough and phlegm in people with COPD responding to the COPD
PPRN survey. This study explored the association between severity of cough and phlegm
and patient-reported outcomes including health-related quality of life.
The burden of cough and phlegm among the study population was high with
approximately 70% of the respondents reported moderate to high levels of cough and/or
phlegm. Considering that cough and sputum production may be underreported in the
COPD population81, symptom burden estimates based on patient-reported data have key
importance. Significantly greater proportion of patients with moderate/high cough and
phlegm reported being current smokers, had worse self-reported dyspnea and greater
numbers of exacerbations in the past year compared to those with no/low cough and
phlegm.
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Our study findings demonstrated significant association between severity of
cough and phlegm and greater levels of fatigue, anxiety, and depression, higher pain
interference and sleep disturbance, and lower social abilities and physical function (as
measured by the Patient Reported Outcome Measurement Information System (PROMIS)
instrument). Other important findings from this chapter concern the longitudinal portion
of this study. The patient-reported improvements in cough and phlegm over time were
associated with better quality of life measured by PROMIS-29 at the follow-up. The
findings of consistent association between high levels of cough and phlegm and worse
patient-reported quality of life emphasize the need for new therapies specifically
targeting these symptoms.
Chapter Four of this research examined prevalence of Pseudomonas aeruginosa
(PA) colonization and presence in sputum of NCFB patients within the BRR. This study
posited the association between presence of PA and NCFB severity using two modified
bronchiectasis severity assessment instruments. Over a quarter of the study population
had presence of PA, and 13.6% presented with chronic PA colonization. Patients with PA
presence had significantly worse pulmonary function as shown by FEV1 and FVC %
predicted, and greater number of exacerbations and hospitalizations due to pulmonary
illness, compared to those without PA. An important contribution of this work was to
show that while the severity indices require chronic colonization of PA, evidence of a
single PA infection was significantly associated with severity on both indices.
The Bronchiectasis Severity Index (BSI), which was designed to identify patients
at high risk for mortality, exacerbations, hospitalizations, and worse quality of life,25 and
the FACED,26 were modified to adapt to the BRR data collection. Our findings supported
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earlier reported differences in severity classification between the BSI and FACED.118 Our
study demonstrated that m-BSI and m-FACED show fair agreement (kappa=0.2632) in
classifying severity of NCFB. The results of the unadjusted and adjusted multinomial
regression analyses demonstrated positive association between presence of PA and
severity of bronchiectasis estimated using m-BSI and m-FACED. These findings support
previous research and underline the importance of early identification and targeted
treatment of PA to reduce disease severity.
5.2

Strengths and Limitations
This dissertation research assessing patient outcomes in people with three chronic

pulmonary diseases yielded several important findings. One of the main strengths of this
research is the large number of patients included in each study as well as detailed data
collected on various demographic and clinical characteristics of the participants. In
addition to the baseline, the COPD PPRN study also utilized follow-up data on patientreported outcomes after one year. Despite the richness of the data, the findings of this
research should be interpreted with caution in view of several limitations related to the
registry-based observational nature of the studies.
Disease-specific registries and analyses based on patient registry data are gaining
popularity.120 Systematic collection of data on specific diseases allows for follow-up of
trends in diagnosis, treatment, and outcomes.121 The primary purpose of patient registries
is mainly to aid in research of natural history of various diseases.121 In addition, registry
data are also used for hypothesis generation, describing patient-reported outcomes, risk
factors and exposures.121,122
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Some of the limitations that are recognized in registry-based studies are selection
bias, confounding by disease severity, channeling bias, immortal time bias, as well as
several other limitations of the observational studies.120 In addition, research using only
baseline data is not able to provide causal inference due to cross-sectional nature of the
studies.
This dissertation research is based on secondary data from several US diseasespecific registries. Chapter Two study utilized data collected from participants of
AlphaNet, a not-for-profit health management organization that coordinates management
and treatment of individuals with AATD and lung disease in the US27,42. Only patients
with more severe genotypes ZZ and SZ were included in this study. Considering that a
greater number ZZs develop lung disease relative to SZs, and only patients with lung
disease were invited to enroll in ADMAPP, the potential of ascertainment bias cannot be
excluded. In addition, the findings of this study cannot be generalized to patients with ZZ
and SZ genotypes without lung disease.
Chapter Three study is based on the COPD PPRN patient-reported data. Only data
obtained from patients with self-reported physician-diagnosed COPD were included in
this study, which may have introduced potential selection bias. In addition, self-reported
data including presence of comorbidities, frequency of physician, ER visits and
hospitalizations is subject to a recall bias. Another important to note limitation of this
study is use of classification of severity of cough and phlegm based on CAT scores for
questions pertaining to these symptoms, which is not a widely used classification and
may have introduced a misclassification bias.
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Chapter Four of this research utilized data collected from patients with NCFB
within the BRR. The BRR is a multi-site registry, and participants are recruited from
tertiary referral institutions and may not be representative of the general population of
individuals with NCFB. In addition, patients within individual centers might be more
correlated in their characteristics and therapy options. Our study analysis did not take into
account potential variability in these characteristics across the clinical sites. These tertiary
referral institutions have high interest in NTMLD; hence, the BRR population may be
enriched for patients with NTM. The BRR data collection takes place using medical chart
abstraction, which may have led to recording errors, missing entries and reporting and
non-response biases. Another important limitation of this study is use of modified disease
severity indices to adapt to the BRR data collection.
Although disease-specific registries intrinsically are subject to potential biases
and limitations, they often have the ability to address research questions that could
potentially have a long-term influence on disease prevention and development of new
therapies.10 In the case of uncommon and rare diseases such as AATD and
bronchiectasis, registry-based studies often represent the only source of data for research.
5.3

Future Research
This dissertation research underlined many important recommendations for future

research and considerations for management of chronic pulmonary diseases. Some
prevalent chronic lung diseases, like COPD, are well researched, but further studies are
needed to fully assess burden of specific symptoms of the disease such as cough and
phlegm. The findings in Chapter Three highlight the needs for future research and
development of new pharmacotherapies specifically targeting prevalent COPD symptoms
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like cough and phlegm. Regrettably, no new and effective cough medication has been
developed by the pharmaceutical industry in over a century.64 Future research is
recommended to better understand patient-perceived burden of COPD symptoms, disease
outcomes and quality of life including mood and social and physical functioning. Patientreported data is invaluable in assessing patient-perceived severity of disease, including its
burden on daily life and activities.
Less common respiratory diseases such as AATD and Bronchiectasis have started
receiving a significant amount of attention from the scientific community leading to
increased interest in research and development of new treatments. Disease-specific
registries play important roles in continued research of these conditions, as frequently
data collected by the registries is the largest source of information on natural history of
rare diseases.
The findings of the study in Chapter Two highlight the value of disease
management programs in addressing many questions regarding the natural history of rare
diseases such as AATD as well as sustained and tailored support provided to the patients
with uncommon diseases. Our study findings underline the differences in demographic
and clinical characteristics of patients with AATD with ZZ and SZ genotypes. Our results
suggest that patients with less severe deficient genotype perceive their disease risk as low
and do not fully comply with healthy lifestyle recommendations of the disease
management program. Considering the above findings, future research should consider
the extent to which genotype-specific health promotion intervention would be useful.
Future studies should consider including collection of additional clinical data to enhance
future outcome research.
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As mentioned in Chapter Four, further research is needed to fully understand the
multidimensional nature of NCFB. Pathogenic microorganisms such as Pseudomonas
aeruginosa (PA) may potentially play a role in the development of bronchiectasis
according to the “vicious cycle” hypothesis.24,79 Hence, early identification of prevalent
pathogens such as PA and timely start of appropriate antibacterial therapy remain highly
important in patients with NCFB.111 Future longitudinal studies are recommended to
assess clinical outcomes and prognosis over time in this patient population.
This dissertation research has contributed to the characterization of the
epidemiology of chronic pulmonary disease burden. These studies expand the amount of
knowledge available on disease severity, health behaviors and patient-perceived
outcomes in three chronic lung diseases, and emphasize the need for further research and
development of new treatment options to improve patients’ prognosis.
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